

## CURRICULUM VITAE

**NAME**                    **Mark Scott Blumenkranz**

**ADDRESS**

Byers Eye Institute at Stanford  
2452 Watson Court  
Palo Alto, CA 94303  
Office Telephone: 650-725-0231  
Fax: 650-498-5834  
Academic E mail: mark.blumenkranz@stanford.edu  
Other E mail: mark.s.blumenkranz@gmail.com

**TITLE**

HJ Smead Professor Emeritus  
Director of the Ophthalmic Innovation Program  
Byers Eye Institute at Stanford  
Department of Ophthalmology  
Stanford University School of Medicine

**POST DOCTORAL AND RESIDENCY TRAINING**

1972	Brown University, Providence, Rhode Island	A.B.
1975	Brown University, Providence, Rhode Island	M.D.
1976	Brown University, Providence, Rhode Island (Biochemical Pharmacology)	M.M.S.
1975-1976	Surgical Internship Stanford University Medical Center, Palo Alto, California	
1976 -1979	Ophthalmology Residency Stanford University Medical Center, Palo Alto, California	
1979	Chief Resident Stanford University Medical Center, Palo Alto, California	

**POST DOCTORAL AND RESIDENCY TRAINING** (Continued)

1979-1980	Fellowship Retinal and Vitreous Diseases Heed Fellow (1980) Bascom Palmer Eye Institute, University of Miami School of Medicine Miami, Florida	
2004	Stanford Executive Program Stanford Graduate School of Business, Stanford, CA	

**ACADEMIC APPOINTMENTS**

1980 - 1985	Assistant Professor Department of Ophthalmology, Bascom Palmer Eye Institute University of Miami School of Medicine, Miami, Florida
1985 - 1992	Adjunct Associate Professor Eye Research Institute, Oakland University, Rochester, Michigan
1986 - 1992	Clinical Associate Professor Kresge Eye Institute, Wayne State University School of Medicine Detroit, Michigan
1992 - 1997	Clinical Professor of Ophthalmology Stanford University School of Medicine, Stanford, California
1997 - 2015	HJ Smead Professor and Chairman Department of Ophthalmology Stanford University School of Medicine, Stanford, California
2017 - Present	HJ Smead Professor Emeritus, Stanford University School of Medicine
2007- Present	Faculty member, Stanford Bio-X and Byers Center for Biodesign

**HONORS AND AWARDS**

1975	Sigma XI (Scientific Honor Society), Brown University
1979	Foster Ophthalmologic Prize, Stanford University
1980	Heed Foundation Fellow
1982, 1984	Special Manpower Award, (Research to Prevent Blindness)
1986	Honor Award - American Academy of Ophthalmology
1988	Heed Society Award
1992	Rosenthal Foundation Award in Visual Sciences
1992 - Present	The Best Doctors in America
1996	Senior Honor Award - American Academy of Ophthalmology
1997 - Present	Who's Who in the World
2005	Alcon Research Institute Award
2005	Gertrude Pyron Award for Outstanding Achievement in Retina Research – ASRS
2006	The W. Richard Green Award Lecture – Macula Society

**HONORS AND AWARDS** (Continued)

2008	AAO Life Achievement Honor Award
2009	Foundation Fighting Blindness – Visionary Award
2011	AOA Brown University
2013	The Jackson Memorial Award Lecture AAO and AJO
2013	Kreissig Award Lecture, Euretina
2014	Charles Schepens Award Lecture, American Academy of Ophthalmology
2016	The Gass Award Lecture, The Retina Society
2016	The Wacker Prize Lecture, The Club Jules Gonin

2018 OIS Lifetime Innovator Award  
2019 WW Kean Distinguished Medical Alumni Award Brown University  
2019 Albion Walter Hewlett Award Stanford Medicine  
2019 American Academy of Ophthalmology Guest of Honor

**ADMINISTRATIVE POSITIONS**

1980 - 1985 Experimental Vitreoretinal Research Fellowship Director  
Bascom Palmer Eye Institute, Miami, Florida

1986 - 1989 Director and Founder, Vitreoretinal Fellowship Program  
Kresge Eye Institute, Wayne State University, Detroit, Michigan

1985 - 1989 Chief, Vitreoretinal Surgery  
Kresge Eye Institute, Wayne State University, School of Medicine  
Detroit, Michigan

1986 - 1992 Director and Founder, Vitreoretinal Fellowship Program  
William Beaumont Hospital-Oakland University

1987 - 1989 Program Chairman, Michigan Ophthalmological Society

1987 - 1990 Program Committee, Association for Research in Visual Science and  
Ophthalmology (ARVO)

1987 - 1991 Chairman, Research Committee, The Macula Society

1987 - 1991 Executive Committee, The Macula Society

1987 - 1994 Publications Committee - Silicone Oil Study

1989 - 1992 Preferred Practice Plan Committee Retina Panel -  
American Academy of Ophthalmology

1989 - 1992 Media Ophthalmology Committee - American Academy of  
Ophthalmology

1990 Chairman, Retina Section, Association for Research in Visual Science and  
Ophthalmology (ARVO)

1990 - 1992 Chief, Vitreoretinal Section, Department of Ophthalmology  
William Beaumont Hospital, Royal Oak, Michigan

1992 - 1997 Co-Director, Retinal Service, Department of Ophthalmology  
Stanford University Medical Center, Stanford, California

1992 - 1998 Director Continuing Ophthalmic Education

Stanford University Medical Center, Stanford, California

1992 - 1995 Membership Committee, Retina Society

1992 - 1996 Ophthalmic Drug Committee  
American Academy of Ophthalmology

1992 - 1996 Liaison Committee to Ophthalmic Devices Panel FDA  
Retina Society

1993 - 1994 Technology Assessment Council  
Stanford University Medical Center, Stanford, California

1996 - 1997 Director of Clinical Programs  
Department of Ophthalmology  
Stanford University Medical Center, Stanford, California

1997 - 2015 Chairman  
Department of Ophthalmology  
Stanford University School of Medicine, Stanford, California  
Founding Director Byers Eye Institute at Stanford

1998 - 2002 Capital Budget Committee  
Stanford University Hospital, Stanford, California

2000 - 2002 Co-Chair Capital Budget Committee  
Stanford University Hospital, Stanford, California

1999 - 2000 Program Committee, Retinal Subspecialty Day  
American Academy of Ophthalmology

2001 -2002 Program Chairman, Retinal Subspecialty Day  
American Academy of Ophthalmology

1997 – 2015 QA-QI Committee, Ophthalmology Service  
Stanford University, Stanford, California

1997 – 2015 Executive Committee of the School of Medicine  
Stanford University, Stanford, California

1998 – 2015 Operating Room Medical Committee  
Stanford Hospital, Stanford, California

2007 - 2008 President, AUPO

2007 – 2009 Vice President, Retina Society

2008 – Present Center for Health Policy/Center for Primary Care & Outcomes Research

Member Stanford University, Stanford, California

2009-2011 President, Retina Society

2009-2011 Executive Committee Macula Society

2011-2012 President Macula Society

**BOARD MEMBERSHIPS**

1994 - Present Delegate for Ophthalmology  
Stanford University Hospital Medical Board, Stanford, California

1993 - 1998 Board of Directors  
Maimonides Society, San Francisco, California

1994 - 1998 Board of Directors, Midlabs, San Leandro, California

1994 - Present Board of Directors  
Prevent Blindness Northern California, San Francisco, California

1995 - 1998 Board of Directors, Ophthalmic Imaging Systems, Sacramento, California

1996 - 1998 Board of Overseers,  
Brown University School of Medicine, Providence, Rhode Island

1999 - 2002 Corporation Committee on Biomedical Affairs,  
Brown University, Providence, RI

1998 - 2002 Board of Directors  
Foundation Fighting Blindness, Northern California Chapter

1999 - 2004 Scientific Advisory Board, Eyetech Pharmaceuticals, New York, NY

2000 – 2004 Board of Directors, Oculex Pharmaceuticals, Sunnyvale, California

2002 - 2004 Ad Hoc Scientific Advisory Board  
Research to Prevent Blindness (RPB), New York, New York

2001 - 2008 National Scientific Advisory Board  
Foundation Fighting Blindness (FFB), Owings Mills, Maryland

2002 - 2009 Board of Trustees, American University Professors of Ophthalmology  
(AUPO) San Francisco, CA

2002 - 2019 Brown University Corporation Trustee, Providence, RI

2004 - 2013 Board of Directors, Optimedica Corporate, Santa Clara, CA

2004 - 2010 Board of Directors, Macusight, Union City, CA

2005 - 2018 Chair, Corporation Medical School Committee  
Brown University, Providence, RI

2005 - Present Board of Directors, Retina Society

2006 - 2011 Board of Directors, PEAK Surgical Corporation, Palo Alto CA

2008 - 2019 Board of Fellows, Brown University Corporation, Providence, RI

2008 - 2015 Board of Directors, Macula Society

2009 - 2011 President, The Retina Society

2009 - 2016 Board of Directors Adverum Biotechnologies

2009 - 2020 Board of Directors Verana Health (formerly Digisight Technologies)

2010- 2012 Past President, Retina Society

2014 - 2015 Past President, Macula Society

Member and Fellow, Association for Research in Visual Science and Ophthalmology

2015 - 2019 Steering Committee, Audacious Goals Initiative NEI/NIH

**EXAMINING BOARD MEMBERSHIPS**

1984 – 2006 Associate Examiner  
American Board of Ophthalmology

1994 - 2001 Panel Member Written Certificate Renewal Committee  
Chairman Retina Section, American Board of Ophthalmology

**MEDICAL LICENSURE AND BOARD CERTIFICATIONS**

1976 National Board of Medical Examiners - #156721

1976 California Medical License - #G32202

1980 Florida Medical License - #037477

1980 American Board of Ophthalmology

1985 Michigan Medical License - #49317

**ORGANIZATIONAL MEMBERSHIPS**

American Board of Ophthalmology

Fellow, American Academy of Ophthalmology  
American Medical Association (AMA)  
Association for Research in Vision and Ophthalmology (ARVO)  
Macula Society  
Club Jules Gonin  
Retina Society  
American Society of Retinal Specialists  
Society of Heed Fellows  
Brown Medical Association  
Stanford Medical Association  
Aspen Retinal Detachment Society  
California Medical Association  
California Association of Ophthalmology  
Pan American Association of Ophthalmology  
American Uveitis Society  
Gass Fluorescein Club (AAO)

**EDITORIAL RESPONSIBILITIES**

1984 – Present	Editorial Board – RETINA
1990 – 2007	Editor - Abstracts Section, Retina
1984 – Present	Reviewer - Archives of Ophthalmology
1985 – Present	Reviewer - Ophthalmology
1986 – Present	Reviewer - Investigative Ophthalmology
1986 – Present	Reviewer - Graefe's Archives for Clinical and Experimental Ophthalmology
1987 – Present	Reviewer - Current Eye Research
1990 – Present	Reviewer American Journal of Ophthalmology
1991 – Present	Editorial Advisory Board – Vitreoretinal Surgery and Technology
1992 – 1996	Editorial Board – Graefe's Archives for Clinical and Experimental Ophthalmology
1994 – 2002	Editorial Board – Ophthalmology
1994 – 1996	Editor in Chief – Vitreoretinal Interfaces: A CD-ROM Publication
2002 – 2005	Executive Editor – Retina
2002 – 2008	Editorial Board – American Journal of Ophthalmology
1999 – Present	Editorial Board – Ophthalmology Times
1999 – 2005	Member of Writing Committee TAP and VIP Trials

**HOSPITAL APPOINTMENTS**

1980 - 1985      Attending Physician  
Anne Bates Leach Eye Hospital,      Miami, Florida

1985 - 1992      Staff Physician  
William Beaumont Hospital, Royal Oak, Michigan

1985 - 1992      Attending Physician  
Detroit Medical Center,      Hutzel Hospital, Detroit, Michigan

1985 - 1992      Staff Physician  
St. Joseph Mercy Hospital,  
Catherine McAuley Health Center, Ann Arbor, Michigan

1986 - 1992      Staff Physician  
Children's Hospital of Michigan, Detroit, Michigan

1992 - Present      Attending Physician  
Stanford University Medical Center, Stanford, California

**STUDY SECTION AND COUNCIL MEMBERSHIPS**

1983 - 1985      Special Reviewer, National Institutes of Health  
Visual Sciences Study Section, Veterans Administration

1984 - 1986      Advisory Committee  
Fellowship Awards: Fight for Sight

1991 - Present      Executive Committee  
Ronald G. Michels Foundation, Member of Fellowship Selection Committee

1990 - 1997      Alcon Retinal Advisory Council

**RESEARCH GRANTS**

1983 - 1992      National Eye Institute  
R01 EY03934 Principal Co-investigator  
A Pharmacologic Approach to Intraocular Proliferation #6371-04

1985 - Present      Treating Surgeon  
Macular Photocoagulation Study  
National Institute of Health  
5U01-EY-02563-01 through 5U01-EY-02563-06

1985      National Eye Institute  
Treating Physician  
1 U01 EY 06340-1  
Cryotherapy for Retinopathy of Prematurity

- 1985 University of Southern California  
Ophthalmic Surgeon, Silicone Oil Study  
Editorial Committee
- 1987 William Beaumont Hospital Research Institute  
Principal Investigator  
Identification of Mitogenic Factors from Intraocular Fluid of Patients with PVR  
RI-8709
- 1988 William Beaumont Hospital Research Institute  
Principal Investigator  
Identification of Mitogenic Factors from Intraocular Fluid of  
Patients with PVR  
RI-88-19
- 1989 William Beaumont Hospital Research Institute  
Principal Investigator  
Effects of Low Molecular Weight Heparin on Cell-mediated Contraction and  
Proliferation by Ocular Cells.  
RI #89-21
- 1990 The Macular Foundation  
Principal Investigator for the Macula Society  
Potential Hazards for Argon Blue-Green Laser Photocoagulation
- 1990 William Beaumont Hospital Research Institute and  
Oakland University Eye Research Institute  
Principal Investigator  
The Interaction Between Light and Photosensitizing Drugs  
Project 90-23 RC 795
- 1996 – 2002 QLT Corp  
Co-Investigator  
  
A Randomized, Placebo-Controlled, Masked, Multicenter,  
Phase III Study of the Treatment of Subfoveal Choroidal  
Neovascularization (CNV) Secondary to Age-Related  
Macular Degeneration (AMD) Using Photodynamic  
Therapy (PDT) with Liposomal BPD-MA (Verteporfin)
- 1998 - 2002 QLT Corp.  
Principal Investigator  
A Randomized, Placebo-Controlled, Masked, Multicenter, Phase IIIB Study  
of the Treatment of New Subfoveal Choroidal Neovascularization Secondary  
to Age-Related Macular Degeneration of Pathologic Myopia Using  
Photodynamic Therapy with Liposomal BPD-MA (Verteporfin)

- 1998 - 2000 Agouron Pharmaceuticals Principal Investigator  
A Phase II, Randomized Double-Masked, Placebo- Controlled Study of the Matrix Metalloprotease Inhibitor AG3340 in Patients with Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration
- 1999 – 2000 Eli Lilly  
Principal Investigator  
Protein Kinase C Beta Inhibitor – Diabetic Retinopathy Study
- 1999 – 2000 Eli Lilly  
Principal Investigator  
Protein Kinase C Beta Inhibitor - Diabetic Macular Edema Study
- 1999 – 2001 ISTA Pharmaceuticals  
Co-Investigator  
Phase III Safety and Efficacy Study of Vitrase (Hyaluronidase) for  
Ophthalmic  
Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage
- 2000 – 2003 Carl Zeiss  
Co-Principal Investigator  
Evaluation of Commercial Prototype for PEAK Technology
- 2000 – 2002 Kirsch Foundation  
Principal Investigator  
Photodynamic Angiography with Verteporfin (Visudyne)
- 2001 – 2006 VISX, Inc.  
Principal Investigator  
New Therapies for Age-Related Macular Degeneration and Other Causes of Visual Loss

**VISITING PROFESSORSHIPS AND INVITED SPECIAL LECTURES** (Partial List)

- November 1982 Visiting Professor  
7<sup>th</sup> Medcom American Military Ophthalmologists, Heidelberg, Germany
- November 1983 Visiting Professor  
Medical College of Wisconsin, Milwaukee, Wisconsin
- December 1983 Visiting Professor  
Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland
- July 1984 Visiting Professor Long Island Jewish Hospital, North Shore Medical Center, New York,
- November 1985 Visiting Professor

Wills Eye Hospital, Philadelphia, Pennsylvania

November 1985      Visiting Professor  
Venezuelan Congress of Ophthalmology, Caracas, Venezuela

January 1986      Visiting Professor  
Retina Service - Massachusetts Eye & Ear Infirmary, Boston, Massachusetts

June 1987          Visiting Professor  
Emory University, Atlanta, Georgia

October 1987      Visiting Professor  
Manhattan Eye & Ear Infirmary, New York, New York

June 1988          Visiting Professor  
Pennsylvania Academy of Ophthalmology, Hershey, Pennsylvania

July 1988          Douglas C. McFarland Lecturer  
The Association for the Education and Rehabilitation of the Blind and  
Visually Impaired, Montreal, Quebec, Canada

September 1988   Visiting Professor  
Brazilian Council of Ophthalmology, Rio de Janeiro, Brazil

September 1988   Tilles-Weidenthal Lecture  
St. Lukes Hospital, Cleveland, Ohio

July 1989          Visiting Professor  
University of Illinois, Chicago, Illinois

October 1989      Visiting Professor  
Yale University, New Haven, Connecticut

February 1990     Visiting Professor  
Manhattan Eye & Ear Infirmary, New York, New York

June 1990          Guest of Honor  
New England Ophthalmologic Society

March 1991         Special Invited Lecturer  
Dallas Academy of Ophthalmology, Dallas, Texas

September 1991   Invited Lecturer Bietti Foundation  
3<sup>rd</sup> International Congress on Vitreoretinal Surgery, Rome, Italy

September 1992   Visiting Professor  
Department of Ophthalmology, University of California San Francisco

September 1992      Visiting Professor  
Jules Stein Eye Institute, UCLA,      Los Angeles, California

December 1992      Ronald G. Michels Memorial Lecture  
Baltimore, Maryland

May 1993              Visiting Professor  
Scheie Eye Institute, The University of Pennsylvania, Philadelphia,

September 1993      Visiting Professor and Knobloch Lecturer  
University of Minnesota, Minneapolis, Minnesota

February 1994      Visiting Professor  
Fondacion de la Valenciana, Mexico City, Mexico

March 1994            Invited Special Lecturer  
Utah Ophthalmologic Society Annual Symposium

April 1994            Visiting Professor  
Universidad Autonoma Barcelona, Spain

April 1994            Invited Guest Lecturer  
Duke University Vitrectomy Symposium, Durham, North Carolina

August 1994          Invited Guest Lecturer  
San Diego Eye Bank Annual Symposium, San Diego, California

August 1994          Invited Guest Lecturer  
Hadassah Hospital Vitreoretinal Symposium, Jerusalem, Israel

January 1995          Featured Speaker  
  
Royal Hawaiian Eye Society, Tufts University, Medford, Massachusetts

April 1995            Visiting Professor  
Greater New York Lecture Series, Manhattan Eye & Ear Infirmary  
New York, New York

January 1996          Visiting Professor  
UC San Francisco, Department of Ophthalmology

February 1996        Featured Speaker  
Squaw Valley Retinal Conference, Olympic Valley, California

March 1996            Featured Speaker  
Aspen Retinal Detachment Society

April 1996            McPherson Lecture, University of Wisconsin, Madison, Wisconsin

May 1996                    Visiting Professor  
University of Washington, Seattle, Washington

June 1996                    Special Invited Guest  
GLADAOF, Bogota, Columbia

November 1996             Invited Guest Lecturer  
Infections of the Anterior and Posterior Segment  
Cleveland Clinic, Cleveland, Ohio

December 1996             Visiting Professor  
Macular Surgery, Long Island Jewish Hospital, New York, New York

February 1997             Invited Guest Lecturer  
Symposium Internacional Moacyr Alvaro Escula Paulista Medicina  
Sao Paolo, Brazil

February 1997             Invited Guest Lecturer  
Squaw Valley Retina Symposium, Photodynamic Therapy  
Olympic Valley, California

July 1997                    Paul Cibis Memorial Lecture  
Pharmacologic Treatment of Choroidal Neovascularization  
Macinac, Michigan

October 1997               Delbert Nachazel Memorial Lecture  
Pharmacologic Approaches to Age Related Macular Degeneration  
William Beaumont Eye Institute, Royal Oak, Michigan

February 1999             Special Invited Guest of The Vth International Congress of the Pan Arab African  
Council of Ophthalmology and the 95<sup>th</sup> Congress of Egyptian  
Ophthalmological Society  
  
Photodynamic and Pharmacologic Therapy for Age-Related Macular  
Degeneration, Cairo, Egypt

March, April 1999        Visiting Professor – Invited Lecturer  
The Chinese University of Hong Kong, Hong Kong Eye Hospital  
New Therapeutic Approaches to Age-Related Macular Degeneration  
Hong Kong, China

March, April 1999        Special Invited Guest of Shanghai Vitreoretinal Institute and  
Shanghai Medical Association, Shanghai, China  
1) Photodynamic Therapy  
2) Pharmacologic Treatment of Macular Degeneration  
3) Retinal and Choroidal Infections

- April 1999           Invited Guest Lecturer  
Greater New York Ophthalmology Clinical Lecture Series  
Manhattan Eye, Ear & Throat Hospital, New York
- April 1999           Visiting Professor  
UC Davis, Department of Ophthalmology, Sacramento, California
- April 1999           ASCRS – Invited Lecturer  
Seattle, Washington  
1) Vitreoretinal Surgery Update for the Anterior Segment Surgeon  
2) Vitreoretinal Complications from Cataract Surgery
- September 1999     Invited Guest Speaker  
Cole Eye Institute Inauguration  
Cleveland Clinic Foundation, Cleveland, Ohio  
1) The Future of Clinical Practice in Ophthalmology  
2) Antiangiogenic Drugs
- September 1999     Invited Guest Lecturer  
Advanced Vitreous Surgery Course, Kyoto, Japan
- October 1999        Invited Guest Lecturer  
American Academy of Ophthalmology – Pre-academy Retina Update  
Orlando, Florida
- January 2000        Invited Guest Lecturer  
Retina 2000, Tufts University  
Basic Principles of Photodynamic Therapy  
Maui, Hawaii
- February 2000       Invited Guest Lecturer  
Spanish Vitreo-Retinal Society Meeting  
Bilbao, Spain  
1) New Developments in Photodynamic Therapy  
2) A New Cutting Tool for Vitreoretinal Surgery (PEAK)  
3) Current Concepts on Vitreomacular Traction
- March 2000          Invited Guest Speaker  
Retina Service 40<sup>th</sup> Anniversary, Wills Eye Hospital  
Philadelphia, Pennsylvania
- March 2000          Invited Guest Speaker  
Vail Vitrectomy Congress, Vail, Colorado
- April 2000           Invited Guest Speaker  
Duke University  
12<sup>th</sup> Advanced Vitreous Surgery Course

June 2000	Invited Guest Speaker Johns Hopkins University, Wilmer Eye Institute Age Related Macular Degeneration Update: 2000 Baltimore, Maryland
July 2000	Invited Guest Speaker International Symposium on Macular Degeneration and Foveal Translocation Hong Kong, China
September 2000	Invited Special Speaker Dedication of The Cole Eye Institute, Cleveland Clinic
October 2000	Guest of Honor Japanese Vitreoretinal Society, Kobe, Japan
May 2001	Special Invited Guest Lecturer Cole Eye Institute, Cleveland Clinic
October 2001	Inaugural Lincoff Lecture Cornell University, New York, New York
February 2002	Invited Speaker Bascom Palmer Eye Institute 40 <sup>th</sup> Anniversary
August 2002	Invited Speaker VisionQuest, San Francisco
May 2003	Minisymposium ARVO, Miami, Florida
June 2003	Norton Lecture Bascom Palmer Eye Institute
November 2003	Invited Speaker Shiley Eye Institute, San Diego
January 2004	4 <sup>th</sup> Annual Doheny Eye Institute Vision Research Seminar Los Angeles, California 1) Extended delivery of steroid to the posterior segment for macular edema 2) The Stanford vision chip: A progress report
April 2004	Minisymposium: Steroid vs. Other Anti-Angiogenic Agents to Treat Retinal Vascular Disease ARVO, Ft. Lauderdale, Florida

November 2004	Guest of Honor New England Ophthalmological Society
February 2006	W. Richard Green Award Lecture Macula Society Annual Meeting The Influence of Power and Pulse Duration on the Retinal Laser Lesion
July 2005	ASRS 2005 Pyron Award Lecture - Clinical Research and Vitreoretinal Practice: The Impact of Rapid Technology Change and Quantitative Modeling in the Decision-making Process
June 2006	Irvine Lecture Doheny Eye Institute
February 2006	W Richard Green Award Lecture Macula Society
January 2007	Invited Speaker Hawaiian Eye 2007 New Development in Retinal Lasers New Microsurgical Devices for Vitreoretinal Applications Genetic Studies of AMD PDT and Triamcinolone Treatment of Diabetic Macula Edema
March 2007	Invited Speaker Cole Eye Institute, Los Cabos: Advances in Ophthalmology Course Prosthetic Retinal Vision Advances in Retinal Photocoagulation
March 2007	Taylor Smith Lecture Aspen Retinal Detachment Society Evolving Concepts in Retinal Photocoagulation
May 2007	Invited Speaker Cleveland Clinic Foundation Retinal Summit Gene Therapy for Macular Disease New Vitreoretinal Microsurgical Tools New Concepts in Retinal Photocoagulation and Advances in Laser Technology
May 2007	Invited Speaker ARVO The role of Lasers: Lessons from Clinical Trials and New Concepts Invited Speaker: Plenary Session

October 2007	Invited Speaker Retinal Vascular Congress, Vienna Rapamycin (Sirolimus) The use of mTOR inhibition as a treatment for retinal vascular disease associated with proliferation any hyperpermeability
November 2007	Invited Speaker Pre-AAO Retinal Subspecialty Day New Angiographic Imaging Techniques
November 2007	Mentoring in Ophthalmology Eisenhower Medical Center, Palm Springs The Role of Academic Industrial Relationships
January 2008	Irving H. Leopold Lecture Allergan
April 2008	Special Invited Speaker Comprehensive Ophthalmology: Pearls XI Dedication Vanderbilt Eye Institute
May 2008	Special Guest Speaker, French Academy of Ophthalmology
May 2008	The 13 <sup>th</sup> Annual Ruth B. Sauber Distinguished Medical Alumni Lecture Brown University, Providence That's How Eye See It: The Biology and Psychology of Visual Perception
September 2009	Arthur De Voe Lecture Columbia University
January 2010	Principal Speaker Dedication of Byers Eye Institute at Stanford Stanford California
February 2011	Victor Curtin Lecture Bascom Palmer Eye Institute, Miami
October 2012	Special Invited Guest Speaker Cornell Ophthalmology
March 2013	Bryan Lecture Duke University
September 2013	Kreissig Lecture Euretina Congress Hamburg Germany
October 2013	Gavin Herbert Lecture, UC Irvine, Irvine California
November 2013	Edward Jackson Memorial Lecture, American Academy of Ophthalmology New Orleans LA
April 2014	Stanley Chang Lecture, Columbia University New York, New York

- May 2015 Sunil Rao Lecture, Brown University  
Providence Rhode Island
- May 2015 John Milton McLean Award Lecture, Cornell University  
New York, New York
- June 2015 Jerome Bettman Lecture, Stanford University  
Stanford, California
- November 2015 Charles Schepens Lecture, American Academy of Ophthalmology  
Las Vegas Nevada
- July 2016 The Wacker Prize Lecture, Club Jules Gonin  
Bordeaux, France
- September 2016 The Gass Award Lecture, Retina Society  
San Diego CA USA
- June 2019 The Albion Walter Hewlett Award Lecture, Stanford Medicine, Stanford  
CA
- October 2019 Guest of Honor, American Academy of Ophthalmology, San Francisco  
CA

**PRESENTATIONS** (Partial List June 1985 - 2011)

- June 1985 International Laser Symposium  
Histopathology of Endoargon Photocoagulation  
Interlaken, Switzerland
- June 1985 International Retina Meeting  
Clinical and Biochemical Considerations in Fluid Gas Exchange  
Antwerp, Belgium

**PRESENTATIONS** (Continued)

- July 1985 10<sup>th</sup> Anniversary Meeting of Wilmer Retinal Vascular Center  
Risk Factors in Age Related Macular Degeneration  
New Seabury, Massachusetts
- September 1985 International Symposium on Fluorescein Angiography  
Disciform Degeneration and Dermal Elastosis  
Baden-Baden, Germany
- September 1985 American Academy of Ophthalmology  
Risk Factors in Age-Related Maculopathy  
San Francisco, California

- September 1985      American Academy of Ophthalmology  
Treatment of the Acute Retinal Necrosis Syndrome with Acyclovir  
San Francisco, California
- October 1985        Retina Society  
Light Damage and the Retina  
Cleveland, Ohio
- February 1986      Mid-Winter Laser Workshop  
Washington University, St. Louis, Missouri
- March 1986         Spring Vitrectomy Workshop  
Presbyterian Hospital, Dallas, Texas
- April 1986         Retinal Vascular Conference  
Johns Hopkins Hospital  
Wilmer Eye Institute, Columbia, Maryland
- May 1986          ARVO  
Mechanisms in Vitreoretinal Scarring  
Sarasota, Florida
- June 1986         Vitrectomy Workshop  
Rush Memorial Hospital  
Chicago, Illinois
- August 1986        Club Jules Gonin  
Hypocellular Gel Contraction  
Copenhagen, Denmark
- September 1986    Retina Society  
Volume-Pressure Relationships in the Gas-Filled Eye  
Colorado Springs, Colorado

**PRESENTATIONS** (Continued)

- November 1986     American Academy of Ophthalmology  
Uveitis Society  
Diffuse Unilateral Subacute Neuroretinitis  
New Orleans, Louisiana
- January 1987        Advanced Retinal Laser Course  
Ocho Rios, Jamaica
- March 1987         American Society of Contemporary Ophthalmology  
Macular Degeneration  
Las Vegas, Nevada

- March 1987      American Academy of Ophthalmology Regional Update  
Complicated Retinal Detachment  
Chicago, Illinois
- May 1987        ARVO  
Fluoropyrimidines in PVR  
Sarasota, Florida
- June 1987       Macula Society  
Fibrinolytic Therapy for CRVO  
Cannes, France
- July 1987        Nantucket Retina Society  
Giant Tears  
Nantucket, Massachusetts
- September 1987   Retina Society  
Vitreotomy for Diabetic Traction Detachment  
South Hampton, Bermuda
- November 1987    American Academy of Ophthalmology  
Symposium on PVR  
Pharmacologic Treatment for Vitreoretinal Scarring  
Dallas, Texas
- November 1987    American Academy of Ophthalmology  
Acute Multifocal Hemorrhagic Retinal Vasculitis  
Dallas, Texas
- January 1988     Advanced Vitreoretinal Surgery Course  
Sarasota, Florida

**PRESENTATIONS** (Continued)

- February 1988    Macula Society  
Gender Dependence of Macular Holes  
Tucson, Arizona
- April 1988       Annual Conference  
University of Minnesota  
Light Toxicity  
Minneapolis, Minnesota
- August 1988      International Symposium on Proliferative Vitreoretinopathy  
Heparin and Thrombin Effects on Vitreoretinal Scarring  
Koln, Germany

- September 1988      Gonin Society  
Acute Multifocal Hemorrhagic Retinal Vasculitis  
Brugges, Belgium
- October 1988        American Academy of Ophthalmology  
Discussion of Subretinal Membranes in PVR  
Las Vegas, Nevada
- May 1989            ARVO  
Light Damage Thresholds for Retinal Pigment Epithelium are  
Decreased by Chlorpromazine and Chloroquine  
Sarasota, Florida
- May 1989            ARVO  
Inhibition of Fibrin Formation Following Vitrectomy in the  
Rabbit Eye by Infusion of Low Molecular Weight Heparin  
Sarasota, Florida
- May 1989            ARVO  
The Effects of Low Molecular Weight Heparin Fractions on  
Cell-Mediated Contraction and Cellular Proliferation  
Sarasota, Florida
- May 1989            ARVO  
2-D Gel Electrophoresis of Normal and Diseased Human Soluble Vitreous  
Protein  
Sarasota, Florida
- May 1989            ARVO  
Analysis of Intraocular Fluid from Patients with  
Proliferative Retinopathies  
Sarasota, Florida
- October 1989        American Academy of Ophthalmology  
Indications and Results of Relaxing Retinotomy  
New Orleans, Louisiana
- January 1990        Advanced Vitreoretinal Surgery Course  
Sarasota, Florida  
1) Refinements in the Use of Retinotomy, Retinectomy, and Choice of  
Long-Term Tamponade  
2) Choice of Surgical Approach in Complicated Diabetic  
Retinal Detachment
- January 1990        Squaw Valley-Lake Tahoe Retinal Symposium  
Olympic Valley, California

- 1) Surgery of the Macula
- 2) Treatment of Retinal Venous Occlusive Disease
- 3) Surgical and Medical Management of Proliferative Vitreoretinopathy

- March 1990      Aspen Retinal Detachment Society Meeting  
Aspen, Colorado  
1) What's New in Vitreous Humor  
2) Further Illuminations on Retinal Light Damage
- April 1990      ARVO  
Light Damage Thresholds of Retinal Pigment Epithelium are decreased by  
Thioridazine
- May 1990      Pan-American Association of Ophthalmology  
Vitreotomy in Infectious Retinitis  
Orlando, Florida
- August 1990     Nantucket Retina  
Phototoxic Retinopathy  
Nantucket Island, Massachusetts
- September 1990   Gonin Society  
Etiologic Factors in Idiopathic Macular Holes  
Lausanne, Switzerland
- October 1990     American Academy of Ophthalmology  
Advanced Vitreoretinal Surgery Course  
Retinotomy  
Atlanta, Georgia
- January 1991     Jules Stein Advanced Vitrectomy Workshop  
UCLA  
Los Angeles, California

**PRESENTATIONS** (Continued)

- January 1991     Bascom Palmer Uveitis Course  
Bascom Palmer Eye Institute  
Miami, Florida  
1) Retinal Surgery in Uveitis  
2) Diagnostic Vitrectomy and Chorioretinal Biopsy
- February 1991     Squaw Valley Retinal Symposium  
Olympic Valley, California  
1) Surgical Considerations in Uveitis and Allied Disorders  
2) Surgical Considerations of the Vitreoretinal Interface  
3) Surgical Approach to Complicated Diabetic Retinal  
Detachment

- February 1991      4<sup>th</sup> Annual Advanced Vitreoretinal Surgery Course  
Sarasota, Florida
- February 1991      Macula Society  
Description of a Modeling System for Prediction of  
Potential Retinal Drug Toxicity  
Orlando, Florida
- April-May 1991     ARVO  
Sarasota, Florida
- 1) The Effect of Low Molecular Weight Heparin on the Mitogenicity of Intraocular Fluid From Patients with Proliferative Retinopathies.
  - 2) In Vitro Effects of Antioxidants on the Drug-light Interaction Associated with Pigmentary Retinopathies.
  - 3) Amiodarone: Increased Retinal Epithelial Cell Toxicity Following Low-level Near UV Irradiation.
  - 4) Use of a Lipophilic Prodrug-linked 5-FU in Silicone Oil for a Sustained Release System.  
Moderator-Diabetic Retinopathy, Retinal Vascular Disease
- June 1991          Bascom Palmer Eye Institute Residents' Day  
Abstract - Description of a Modeling System for Prediction of Potential Retinal Drug Toxicity  
Miami, Florida
- August 1991        Nantucket Retina  
Amiodarone Ocular Toxicity  
Nantucket Island, Massachusetts
- September 1991    Third International Congress on Vitreoretinal Surgery  
G. B. Bietti Fondazione  
Rome, Italy
- 1) Management of Intraocular Lenses;
  - 2) Use of Vitrectomy;
  - 4) Further Refinements in Adjuvant Pharmacology
- October 1991        American Academy of Ophthalmology, Anaheim, California  
Jules Stein Course:
- 1) Acute Retinal Necrosis and Acute Hemorrhagic Vaso-occlusive Retinopathy: Differential Diagnosis and Treatment
  - 2) Pharmacologic Adjuvants to Retinal Detachment Surgery  
Resolution of Diabetic Macular Edema Associated with a Thickened and Taut Premacular Posterior Hyaloid after Vitrectomy
- Advanced Surgery and Management for the Vitreoretinal Surgeon:
- 1) Refinements in Management Techniques for Crystalline and Intraocular Lens Problems for the Vitreoretinal Surgeon;

3) Strategies and Removal of Submacular Blood and Choroidal New Vessel Membranes

Surgical Management of Posterior Chamber Lens Complications and Alternative Methods of Secondary Implantation

Discussant: Retinal Detachment Linked to Penetrating Keratoplasty

Chairman Scientific Session: Viral Retinitis and Retinal Disease in Immunosuppressed Patients

The Surgical Management of the Malpositioned Intraocular Lens

February 1992

Squaw Valley Retinal Symposium

Olympic Valley, California

- 1) Macular Surgery Indications
- 2) ARN Update
- 3) Pharmacology in Vitreoretinal Surgery

February 1992

Puerto Vallarta Retina Course

Puerto Vallarta, Mexico

- 1) New Instruments and Techniques
- 2) Silicone Oil for Proliferative Diabetic Retinopathy
- 3) Moderator - Vitreous Surgery for Complications of Cataract Surgery
- 4) Dislocated Posterior Chamber IOL'
- 5) Management of Retinal Detachment associated with Acute Retinal Necrosis

February 1992

Macula Society

Phoenix, Arizona

- 1) Further Observations in the Syndrome of Diabetic Macular Edema Associated with Posterior Hyaloidal Traction
- 2) Management of Submacular Hemorrhage with Vitreoretinal Surgery and Subretinal Injection of Tissue Plasminogen Activator

**PRESENTATIONS** (Continued)

March 1992

Retinal Charter Club

St. Thomas, British Virgin Islands

Vitrectomy for Diabetic Macular Edema

May 1992

ARVO

Sarasota, Florida

- 1) 5-Fluorouracil Prodrugs Suspended in Silicone Oil as an Intraocular Slow Release System
- 2) The Effect of Low Molecular Weight Heparin on Proliferative Vitreoretinopathy Induced in the Rabbit Eye
- 3) Pars Plana Lensectomy, Vitrectomy and Transvitreous Diathermy in the Rabbit
- 4) Management of Submacular Hemorrhage with Vitreoretinal Surgery and Subretinal Injection of Tissue Plasminogen Activator
- 5) Photosensitization Thresholds for Retinal Pigment Epithelial Cells are Decreased by Amiodarone

- 6) Toxic Synergistic Effect of Visible Light and Thioridazine (Mellaril) on Human Retinal Pigment Epithelial Cells
- 7) Effect of Vitreous Substitutes on the Proliferation of Human Retinal Pigment Epithelial Cells in Vitro

- September 1992      California Association of Ophthalmology  
Diagnosis and Management of Intraocular Foreign Bodies
- November-1992      Improved Surgical Treatment of Familial Exudative Vitreoretinopathy  
as co-author with Glazer L, Maguire A, and Trese M  
American Academy of Ophthalmology, Dallas, Texas
- Long-acting Gas Tamponade in Diabetic Vitrectomy  
as co-author with Fox G, Iverson D, Ward T, and Teske M  
American Academy of Ophthalmology, Dallas, Texas
- Outcome and Reproliferation Rate in Eyes in which Relaxing Retinotomy  
Was Performed  
American Academy of Ophthalmology, Dallas, Texas
- Discussion of Influence of Silicone Oil on Iris Microangiopathy in  
Diabetic Vitrectomized Eyes  
American Academy of Ophthalmology, Dallas, Texas
- January 1993      Course Director and Lecturer  
Use of Liquid Perfluorochemicals in Ophthalmology  
Stanford University, Stanford, California
- January 1993      Guest Speaker  
Squaw Valley Retina Symposium  
The Silicone Oil Study  
Olympic Valley, California
- March 1993      Guest Speaker  
The Aspen Retinal Detachment Society  
Mechanisms of Ocular Phototoxicity
- April 1993      Course Director and Lecturer  
Macular Surgery  
Stanford University, Stanford, California
- May 1993      Course Director and Lecturer  
Management of the Dislocated Lens  
Stanford University, Stanford, California
- June 1993      Ocular Photosensitization Mechanisms  
Bascom Palmer Alumni Day  
University of Miami, Miami, Florida

June 1993            Intraocular Foreign Bodies  
Stanford Ophthalmology Day, Stanford, California

July 1993            Fundamentals of Diabetic Retinopathy  
Alexian Brothers Hospital, San Jose, California

July 1993            Course Director and Lecturer  
Intraocular and Crystalline Problems  
Alcon Surgical Symposium  
San Francisco, California

September 1993    Posterior Retinal Tears in Diabetes Mellitus  
Retina Society  
San Francisco, California

November 1993     Invited Lecturer  
Surgical Treatment of Ruptured Retinal Macroaneurysm  
New Dimensions in Retina  
Chicago, Illinois

February 1994      Squaw Valley Retinal Symposium  
Use of Intraocular Gases in Ophthalmology  
Olympic Valley, California

February 1994      Macula Society  
Surgical Treatment of Macular Hole  
Palm Springs, California

June 1994           Stanford Ophthalmology Day  
Use of Autologous Tissue Glue in Macular Hole Surgery  
Stanford, California

October 1994       Co-Director and Lecturer  
Vitreoretinal Interfaces  
San Francisco, California

November 1994     American Academy of Ophthalmology  
Use of Autologous Plasma- Thrombin Mixture with Vitrectomy for  
Treatment of Full Thickness Idiopathic Macular Hole  
San Francisco, California

April 1995           Course Director  
Digital Imaging in Ophthalmology  
Stanford University, Stanford, California

June 1995	Treatment of Failed Macular Holes Bascom Palmer Eye Institute Miami, Florida
September 1995	Session Moderator Retina Society Santa Fe, New Mexico
September 1995	Course Director Annual Ophthalmology Conference Stanford University Department of Ophthalmology Stanford, California
March 1996	Silicone Oil and Liquid Perfluorocarbon for PVR Vail Vitrectomy Symposium
February 1996	Course Director Excimer Certification Course Stanford University, Stanford, California
April 1996	Course Director Excimer Certification Course Stanford University, Stanford, California
October 1996	American Academy of Ophthalmology Video Presentation of Vitreoretinal Surgery with H Lewis, et al Chicago, Illinois
October 1996	American Academy of Ophthalmology Management of the Dislocated Lens with R Osher, et al Chicago, Illinois
April 1997	Western Retina Study Club Photodynamic Therapy Napa, California
May 1997	ARVO Ft. Lauderdale, Florida 1) High Repetition Rate Erbium:Yag Laser (200 Hz) For Vitreoretinal Surgery 2) Management of Submacular Hemorrhage Associated With Retinal Arterial Macroaneurysms 3) Tissue Plasminogen Activator in Treatment of Infectious Endophthalmitis:A Pilot Study
March 1998	Western Retina Study Club Photodynamic Therapy Monterey, California

- October 1998            Stanford Medical Lecture Series  
Presentation of Lasers in Medicine: A Human's Eye View  
Bing Luncheon, Los Angeles, California
- November 1998        American Academy of Ophthalmology  
New Orleans, Louisiana  
1) Sensitivity of Digital Photography in Detection of Diabetic Retinopathy  
2) Applications of Photodynamic Therapy for Choroidal Neovascularization in Age-Related Maculopathy with T. Edgar Thomas, AAO Instructional Course
- November 1998        Course Director  
New Developments in Diabetes Care and Diabetic Retinopathy Symposia  
Stanford University, Stanford, California  
1) Expanded Indications for Diabetic Vitrectomy  
2) Telemetric Diabetic Retinopathy Screening
- January 1999            AUPO  
Captive Island, Florida  
Department Restructuring in the New AMC
- February 1999        Course Director  
The First Annual Macular Symposium on Diseases and Surgery  
Stanford University, Stanford, California  
1) Basic Photobiology: Application to Photodynamic Therapy  
2) Current Status and Future Directions for Antiangiogenic Drug Therapy  
3) Protein Kinase C Inhibitors and Other Pharmacologic Agents for Diabetic Retinopathy
- February 1999        22<sup>nd</sup> Annual Macula Society Meeting  
San Diego, California  
Late Macular Hole-A New Complication of Retinal Arterial Macroaneurysm
- December 1999        Surgical Frontiers for Y2K  
San Francisco, California  
Macular Hole and Tractional Syndromes
- March 2000            Retina Update Course  
UCSF, San Francisco, California

- May 2000                   ARVO  
Ft. Lauderdale, Florida  
Photodynamic Therapy II – Preliminary Results from a Phase II Dose-Response Study of Photodynamic Therapy with Motexafin Lutetium (Lu-<sup>177</sup>Lu-<sup>177</sup>Tex™) To Treat Subfoveal CNV
- March 2001                   ARVO  
Ft. Lauderdale, Florida  
1) Evaluation of Toxicity in Vitreoretinal Applications of the Pulsed Electron Avalanche Knife (PEAK)  
2) A Pulsed Liquid Microjet for Ocular Microsurgical Applications  
3) The Role of Digital Fundus Photography in Diabetic Screening
- April 2002                   REACT  
Sydney, Australia  
1) Surgical excision of subfoveal choroidal neovascularization: Current indications, controversies, and technique  
2) A review of antimetabolite pharmacology
- June 2002                   25<sup>th</sup> Annual Macula Society  
Barcelona, Spain  
Advances in tissue engineering for macular pigment epithelial transplantation
- September 2002           Club Jules Gonin  
Montreaux, Switzerland  
The pulsed electron avalanche knife (PEAK) for intraocular surgery in patients with proliferative vitreoretinal disorders
- September 2002           Retina Congress 2002  
San Francisco, CA  
Pulsed electron avalanche knife in vitreoretinal surgery: An update
- January 2003               Atlantic Coast Retina Meeting  
New York, New York  
Vein Occlusions: New Treatments
- February 2003             26<sup>th</sup> Annual Macula Society  
Naples, Florida  
A pilot study and long-term follow-up of intravitreal triamcinolone for central retinal vein occlusion
- March 2003                Western Retina Society  
Napa, California

- April 2003           New Horizons in Ophthalmology  
Boston, MA  
1) New treatment for retinovascular disease  
2.) New instruments for vitreoretinal cutting  
3) Pharmacotherapy of macular disease
- September 2003     Retina Society  
Chicago, IL  
A New Retinal Image Database
- September 2003     VI International Congress  
Rome  
Diagnosis and treatment of macular holes and tractional syndromes  
associated with high myopia. Special considerations
- February 2004       Angiogenesis 2004  
Bascom Palmer Eye Institute, Miami, Florida  
Photodynamic therapy plus intravitreal triamcinolone in clinical practice
- November 2004       SUNY 55<sup>th</sup> Annual Post-Graduate Review Course
- 2006                 Jules Stein Postgraduate Seminar  
Reassessment of Pharmacologic Agents in PVR
- June 2007           Retina Society, Vienna  
Rapamycin (Sirolimus) for the Treatment of Diabetic Macular Edema:  
Preliminary Results of a Prospective Phase I Safety Trial
- September 2007     Retina Society, Boston MA  
Rapamycin for the Treatment of Retinal Vascular Disease: Results of a Phase I  
Study
- December 2007       ASRS, Palm Springs  
Pulsed Micro-Injector for Intravitreal Drug Delivery
- January 2008         Allergan, Irvine, CA  
Irving H. Leopold Lecture
- May 2008            Paris Ophthalmology Society, Paris  
The Expanding Role of Scanning Lasers in Retina Therapeutics and Diagnostics
- August 2008         Club Jules Gonin  
Sirolimus (Rapamycin) for the Treatment of Diabetic Macular Edema.
- September 2008     ASRS, Maui  
Annenberg Mentoring in Ophthalmology

May 2009	ARVO, Fort Lauderdale Lasers – Still the Gold Standard?
January 2011	Retina 2011, Maui Management of Diabetic Retinopathy: New Treatment Algorithms
January 2011	Asia-ARVO, Singapore Update of Stanford Retinal Chip Program
January 2011	SNEC 21 <sup>st</sup> Anniversary International Meeting, Singapore Plenary Lecture
February 23011	Bascom Palmer Eye Institute, Miami Victor T. Curtin Visiting Professor Lecture
September 2011	Retina Society, Rome Presiding Officer

## **BIBLIOGRAPHY**

- 1) Masters Thesis. Brown University, 1976. The identification and characterization of cyclic nucleotide phosphodiesterase in bovine trachelis muscle with special attention to kinetic parameters in the face of varied calcium ion concentrations.
- 2) McCulley JP, **Blumenkranz MS**, Fishman SS. A new technique for color video slit lamp biomicroscopy. *Ophthalmology* 1978; 85:1193-1194.
- 3) Aguilar GL, **Blumenkranz MS**, Egbert PR, McCulley JP. Candida endophthalmitis after intravenous drug abuse. *Arch Ophthalmol* 1979; 97(1):96-100.
- 4) **Blumenkranz MS**, Stevens DA. Endogenous coccidioid endophthalmitis. *Ophthalmology* 1980; 87:974-984.
- 5) **Blumenkranz MS**, Stevens DA. Therapy of endogenous fungal endophthalmitis: Miconazole or Amphotericin-B for coccidioid and candidal infection. *Arch Ophthalmol* 1980; 98(7):1216-1220.
- 6) **Blumenkranz MS**, Gass JDM, Clarkson JG. Atypical serpiginous choroiditis. *Arch Ophthalmol* 1982; 100:1773-1775.
- 7) Fisher JP, Lewis ML, **Blumenkranz MS**, Culbertson WW, Flynn, Jr. HH., Clarkson JF, Gass JDM, Norton EWD. The acute retinal necrosis syndrome. Part I. Clinical manifestations. *Ophthalmology* 1982; 89:1309-1315.
- 8) Culbertson WW, **Blumenkranz MS**, Haines H. Gass JDM, Mitchell KB, Norton EWD. The acute retinal necrosis syndrome. Part II. Histopathology and etiology. *Ophthalmology* 1982; 89:1317-1325.
- 9) **Blumenkranz MS**, Byrne SF. Standardized echography for the detection and characterization of retinal detachment. *Ophthalmology* 1982; 89:831-831.
- 10) Ophir A, **Blumenkranz MS**, Clafin AJ. Experimental intraocular proliferation and neovascularization. *Am J Ophthalmol* 1982; 94:450-457.
- 11) **Blumenkranz MS**, Ophir A, Clafin AJ, Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. *Am J Ophthalmol* 1982; 94:458-467.
- 12) Scuderi J, **Blumenkranz MS**, Blankenship G. Regression of diabetic rubeosis iridis following successful surgical reattachment of the retina by vitrectomy. *Retina* 1982; 2:183-196.
- 13) Culbertson WW, Clarkson JG, **Blumenkranz MS**, Lewis ML. Acute retinal necrosis. *Am J Ophthalmology* 1983; 96(5):683-685 (Editorial).
- 14) Stern WH, **Blumenkranz MS**. Fluid-gas exchange after vitrectomy. *Am J Ophthalmol* 1983; 96:400-402.

**BIBLIOGRAPHY** (Continued)

- 15) **Blumenkranz MS**, Hajek A, Hernandez E, Norton EWD. 5-Fluorouracil new clinical applications in complicated retinal detachment. *Ophthalmology* 1984; 91:122-130.
- 16) **Blumenkranz MS**, Claflin A, Hajek AS. Selection of therapeutic agents for intraocular proliferative disease by cell culture evaluation. *Arch Ophthalmol* 1984; 102:598-604.
- 17) Moffat KP, **Blumenkranz MS**, Hernandez E. The lens capsule and rubeosis iridis An angiographic study. *Can J Ophthalmol* 19:130-133, 1984.
- 18) Clarkson JG, **Blumenkranz MS**, Culbertson WW, Flynn Jr. HH, Lewis ML. Retinal detachment following the acute retinal necrosis syndrome. *Ophthalmology* 1984; 91:1665-1668.
- 19) Jarus G, **Blumenkranz MS**, Hernandez E, Sossi N. Clearance of intravitreal fluorouracil normal and aphakic vitrectomized eyes. *Ophthalmology* 1985 Jan; 92:91-96.
- 20) **Blumenkranz MS**, Gardner T, Blankenship G. Fluid gas exchange after vitrectomy I. Indications, technique and results. *Arch Ophthalmol* 1986; 104:291-296.
- 21) **Blumenkranz MS**, Culbertson WW, Clarkson JG, Dix R. Treatment of the acute retinal necrosis syndrome with intravenous acyclovir. *Ophthalmology* 1986; 93:296-300.
- 22) **Blumenkranz MS**, Russel S, Robey M, Kott-Blumenkranz R, Penneys N. Risk factors in age related maculopathy complicated by choroidal neovascularization. *Ophthalmology* 1986; 93:552-558.
- 23) Culbertson WW, **Blumenkranz MS**, Pepose J, Stewart J, Curtin V. Varicella zoster virus is a cause of the acute retinal necrosis syndrome. *Ophthalmology* 1986; 93:559-569.
- 24) Al Baba F, **Blumenkranz MS**. Malignant melanoma at the site of penetrating ocular trauma. *Arch Ophthalmology* 1986; 104:405-409.
- 25) **Blumenkranz MS**, Hartzler MK, Hajek AS. Selection of therapeutic agents for intraocular proliferative disease. *Arch Ophthalmol* 1987; 105:332-334.
- 26) Flynn HW, **Blumenkranz MS**, Parel JM, Lee WG. Cannulated subretinal fluid aspirator for vitreoretinal microsurgery. *Am J Ophthalmol* 1987; 103:106-108.
- 27) Harris MJ, **Blumenkranz MS**, Wittpenn J, Levada A, Brown R, et al. Geometric alterations produced by encircling scleral buckles. *Retina* 1987; 7:14-19.
- 28) Lewis H, Aaberg TM, Packo KH, Richmond PP, **Blumenkranz MS**, et al. Intrusion of retinal tacks. *Am J Ophthalmol* 1987; 103:672-680.

**BIBLIOGRAPHY** (Continued)

- 29) Browning D, **Blumenkranz MS**, Culbertson WW, Clarkson JD, et al. Association of varicella zoster dermatitis with acute retinal necrosis syndrome. *Ophthalmology* 1987; 94:602-606.
- 30) Olsen KO, **Blumenkranz MS**, Hernandez E, Hajeck A, Hartzler M. Fluorouracil therapy of intraocular Greene's melanoma in the rabbit. *Arch Ophthalmol* 1988; 106:812-815.
- 31) **Blumenkranz MS**, Kaplan HJ, Clarkson JG, Culbertson WW, Williams GA, Kleiner RC, Meissner RH. Acute multifocal hemorrhagic retinal vasculitis. *Ophthalmology* 1988; 95:1663-1672.
- 32) Hartzler M, **Blumenkranz MS**, Hajek A, Daily W, Cheng M, Margherio A. Selection of therapeutic agents for intraocular proliferation disease. III - effects of fluoropyrimidines on cell mediated contraction. *Exp Eye Res* 1989; 48:321-328.
- 33) **Blumenkranz MS**, Clarkson J, Culbertson WW, Flynn HW, Lewis ML, Moo Young GA. Vitrectomy for retinal detachment associated with acute retinal necrosis. *Am J Ophthalmol* 1988; 106:426-429.
- 34) Huang D, **Blumenkranz MS**, Hernandez E, Hartzler M. Uptake and clearance of 5-fluorouridine following subconjunctival and intravitreal injection. *Retina* 1988; 8:205-209.
- 35) **Blumenkranz MS**, Clarkson J, Culbertson WW, Flynn HW, Lewis ML, Moo Young G. Visual results and complications after retinal reattachment in the acute retinal necrosis syndrome. The influence of operative technique. *Retina* 1989; 9:170-174.
- 36) Brouman N, **Blumenkranz MS**, Cox MS, Trese MT. Silicone oil for the treatment of severe proliferative diabetic retinopathy. *Ophthalmology* 1989; 96:759-764.
- 37) Barr CC, **Blumenkranz MS**. New substances in the treatment of proliferative vitreoretinopathy. *Ophthalmology Clinics of North America* 1989; 2(1):187-198.
- 38) Lewis HL, **Blumenkranz MS**. Discussion of subretinal membranes in proliferative vitreoretinopathy. *Ophthalmology* 1989; 96:1403-1414.
- 39) Halperin LS, Lewis H, **Blumenkranz MS**, Gass JDM, Olk RJ, Fine SL. Choroidal neovascular membrane and other chorioretinal complications of acquired syphilis. *Am J Ophthalmol* 1989; 108:554-562.
- 40) Wade ED, Flynn HW Jr., Olsen KR, **Blumenkranz MS**, Nicholson DH. Subretinal hemorrhage management by pars plana vitrectomy and internal drainage. *Arch Ophthalmol* 1990; 108:973-978.
- 41) Heidemann DG, Williams GA, **Blumenkranz MS**. Tissue plasminogen activator and penetrating keratoplasty. *Ophthalmic Surg* Vol 21:364-365, May 1990.

**BIBLIOGRAPHY** (Continued)

- 42) Iverson DA, Ward TG, **Blumenkranz MS**. Indications and results of relaxing retinotomy. *Ophthalmology* 1990; 97:1298-1304.
- 43) Duker JS, **Blumenkranz MS**. Diagnosis and management of the acute retinal necrosis (ARN) syndrome. *Survey of Ophthalmology* 35:327-343, 1991.
- 44) Iverson DA, Katsura H, Hartzler MK, **Blumenkranz MS**. Inhibition of intraocular fibrin formation following infusion of low-molecular weight heparin during vitrectomy. *Arch Ophthalmol* 1991; 109:405-409.
- 45) Maguire AM, **Blumenkranz MS**, Ward TG, Winkelman JZ. Scleral loop fixation for posteriorly dislocated intraocular lenses operative technique and long-term results. *Arch Ophthalmology* 1991; 109:1754-1758.
- 46) **Blumenkranz MS**. Discussion of chickenpox associated acute retinal necrosis syndrome. *Ophthalmology* 1991; 98:1645-1646.
- 47) Farah ME, **Blumenkranz MS**, Bonomo PP, et al. Experimental comparative study of cryotherapy, diathermy and laser therapy via pars plana. *Res Bras Oftalmol* 1991; 50(5):15-27.
- 48) **Blumenkranz MS** - Summary and Comment. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy Four-year results of a randomized trial Diabetic retinopathy study report 5 (Diabetic Retinopathy Vitrectomy Study Research Group. *Arch Ophthalmol* 1990; 108:958-64 Diabetes Spectrum 1991; Vol 4(3):155-158.
- 49) Lewis H, Abrams GW, **Blumenkranz MS**, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. *Ophthalmology* 1992; 99:753-759.
- 50) Ridley ME, McDonald HR, Sternberg P, **Blumenkranz MS**, et al. Retinal manifestations of ocular lymphoma (Reticulum Cell Sarcoma). *Ophthalmology* 1992; 99:1153-1161.
- 51) **Blumenkranz MS**, Ward T, Murphy S, Mieler W, Williams G, Long J. Applications and limitations of vitreoretinal biopsy techniques in intraocular large cell lymphoma. *Retina* 1992; 12:64-70 (Suppl).
- 52) **Blumenkranz MS**, Hartzler M, Iverson D. An overview of potential applications of heparin in vitreoretinal surgery. *Retina* 1992; 12:71-74 (Suppl).
- 53) Ie D, Yannuzzi L, Spaide R, Woodward K, Singerman L, **Blumenkranz MS**. Microrips of the retinal pigment epithelium. *Arch Ophthalmol* 1992; 110:1443-9.

**BIBLIOGRAPHY** (Continued)

- 54) Lewis H, **Blumenkranz MS**, Chang S. Treatment of dislocated crystalline lens and retinal detachment with perfluorocarbon liquids. *Retina* 1992; 12:299-304.
- 55) Dalma-Weiszhausz J, **Blumenkranz MS**, Hernandez E, Hartzler MK. Intraocular extracellular cyclic nucleotide concentrations: The influence of vitreous surgery. *Graefes Arch Clin Exp Ophthalmol* 1993; 231:184-186.
- 56) **Blumenkranz MS**, Azen S, Aaberg T, Boone D, Lewis H, Radtke N, Ryan S, and the Silicone Study Group. Relaxing retinotomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy. Silicone Study Group Report 5. *Am J Ophthalmol* 1993; 116:557-64.
- 57) Fox G, **Blumenkranz MS**. Giant retinal pigment epithelial tears in acute retinal necrosis. *Am J Ophthalmol* 1993; 116:302-6.
- 58) Ward T, Hartzler M, **Blumenkranz MS**, Lin R. A comparison of 5-Fluorouridine and 5-Fluorouracil in an experimental model for the treatment of vitreoretinal scarring. *Current Eye Research* 1993; 12:397-401.
- 59) Hutton WL, Azen S, Bi Fong Lee, **Blumenkranz MS**, Lai M, Mc Cuen B, Han D, Flynn H, Ramsay R, Ryan S, and the Silicone Study Group. The effects of silicone oil removal. Silicone Study Report 6. *Arch Ophthalmol* 1994; 112:778-85.
- 60) Rubsamen P, Flynn H, Civantos J, Smiddy B, Murray T, Nicholson D, **Blumenkranz MS**. Treatment of massive subretinal hemorrhage from complications of scleral buckling procedures. *Am J Ophthalmol* 1994; 118:299-303.
- 61) **Blumenkranz MS**. The use of silicone oil for HIV-related retinal detachment [editorial comment]. *Arch Ophthalmol* 1995; 113(11):1366-8.
- 62) Glazer LC, Maguire A, **Blumenkranz MS**, Trese MT, Green WR. Improved surgical treatment of familial exudative vitreoretinopathy in children. *Am J Ophthalmol* 1995; 120:471-9.
- 63) Melberg NS, Grand MB, Dieckert JP, Barney NP, **Blumenkranz MS**, Boone DE, Folk JC, Stransky TJ. Cotton-wool spots and the early diagnosis of giant cell arteritis. *Ophthalmology* 1995; 102(11):1611-4.
- 64) **Blumenkranz MS**. The use of silicone oil for HIV-related retinal detachment [editorial]. *Arch Ophthalmology* 1995; 113(11):1366-8.
- 65) D'Amico DJ, **Blumenkranz MS**, Lavin MJ, et al. Multicenter clinical experience using an erbium:YAG laser for vitreoretinal surgery. *Ophthalmology* 1996; 103(10):1575-85.

**BIBLIOGRAPHY** (Continued)

- 66) Morse LS, Chapman CB, Elliott D, Benner JD, **Blumenkranz MS**, McCuen BW. Subretinal hemorrhages in proliferative diabetic retinopathy. *Retina* 1997; 17(2):87-93.
- 67) Ohana E, **Blumenkranz MS**. Treatment of reopened macular hole after vitrectomy by laser and outpatient fluid-gas exchange. *Ophthalmology* 1998; 105(8):1398-1403.
- 68) Freeman WR, **Blumenkranz MS**. Age-related macular degeneration: Is help on the way? Editorial. *Ophthalmology* 1998 Sep; 105(9):1585-6.
- 69) Humayun M, Lewis H, Flynn HW Jr, Sternberg P Jr, **Blumenkranz MS**. Management of submacular hemorrhage associated with retinal arterial macroaneurysms. *Am J Ophthalmol* 1998 Sep; 126(3):358-61.
- 70) Fong DS, Fredrick AR Jr., **Blumenkranz MS**, Walton DS. Exudative retinal detachment in X-linked retinoschisis. *Ophthalmic Surg Lasers* 1998; 29(4):332-5.
- 71) Lin D, **Blumenkranz MS**. The role of digital fundus photography in diabetic retinopathy screening. Digital Diabetic Screening Group. *Diabetes Technology & Therapeutics* 1999; Nov(1):477-87.
- 72) **Blumenkranz MS**, Woodburn KW, Qing F, Verdooner S, Kessel D, Miller R. Lutetium texaphyrin (Lu-TeX) a potential new agent for ocular fundus angiography and photodynamic therapy. *Am J Ophthalmol* 2000; 129(3):353-62.
- 73) Shaikh S, Shaikh N, **Blumenkranz MS**. Fluorescein angiographic changes in acute toxic retinopathy associated with polypharmacy. *Retina* 2000; 20(6):685-688.
- 74) Shaikh S, **Blumenkranz MS**. Fluorescein angiographic findings in ocular siderosis. *Am J Ophthalmol* 2001 Jan; 131(1):136-138.
- 75) **Blumenkranz MS**, Ohana E, Shaikh S, Chang S, Coll G, Morse L, De Bustros S. Adjuvant methods in macular hole surgery intraoperative plasma-thrombin mixture and postoperative fluid-gas exchange. *Ophthalmic Surgery Lasers* 2001; 32(3):198-207.
- 76) Naseri A, **Blumenkranz MS**, Horton JC. Terson's syndrome following epidural saline injection. *Neurology* 2001 July 24; 57(2):364.
- 77) Ross RD, Stec LA, Werner JC, **Blumenkranz MS**, Glazer L, Williams GA. Presumed acquired ocular toxoplasmosis in deer hunters. *Retina* 2001; 21(3):226-229.
- 78) Shaikh S, **Blumenkranz MS**. Transient improvement in visual acuity and macular edema in central retinal vein occlusion accompanied by inflammatory features after pulse steroid and anti-inflammatory therapy. *Retina* 2001; 21(2):176-178.

**BIBLIOGRAPHY** (Continued)

- 79) Palanker DV, Miller JM, Marmor MF, Sanislo SR, **Blumenkranz MS**. Pulsed electron avalanche knife (PEAK) for intraocular surgery. *Invest Ophthalmol Vis Sci* 2001 Oct; 42(11):2673-8.
- 80) Palanker DV, Marmor MF, Branco A, Huie P, Miller JM, Sanislo SR, Vankov A, **Blumenkranz MS**. Effects of the Pulsed Avalanche Knife (PEAK) on Retinal Tissue. *Arch Ophthalmol* 2002 May; 120(5):636-40.
- 81) Woodburn K, Engelman C, **Blumenkranz MS**. Photodynamic therapy for choroidal neovascularization A Review. *Retina* 2002 Aug; 22(4):391-405.
- 82) Lin D, **Blumenkranz MS**, Brothers R, Grosvenor D. The sensitivity and specificity of single field nonmydriatic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening A comparison with ophthalmoscopy and standardized mydriatic color photography. *Am J Ophthalmol* 2002 Aug; 134(2):204-13.
- 83) Fletcher DA, Palanker DV, Huie P, Miller J, Marmor MF, **Blumenkranz MS**. Intravascular drug delivery with a pulsed liquid microjet. *Arch Ophthalmol*. 2002 Sept; 120(9):1206-8.
- 84) **Blumenkranz MS**, Bressler NM, Bressler SB, Donati G, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: Three-year results of an open-label extension of 2 randomized clinical trials—TAP Report no. 5. *Arch Ophthalmol* 2002 Oct; 120(10):1307-14.
- 85) Lam D, **Blumenkranz MS**. Treatment of central retinal vein occlusion by vitrectomy with lysis of vitreo-papillary adhesions, subretinal peripapillary TPA injection and photocoagulation. *Am J Ophthalmol* 2002 Oct; 134(4):609-611.
- 86) Bressler NM, Arnold J, Benchaboune M, **Blumenkranz MS**, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes—TAP Report no. 3. *Arch Ophthalmol* 2002 Nov; 120(11):1443-1454.
- 87) Ta C, Egbert P, Singh K, Shriver E, **Blumenkranz MS**, De Kaspar H. Prospective randomized comparison of three day versus one hour preoperative Ofloxacin prophylaxis for cataract surgery. *Ophthalmology* 2002 Nov; 109(11):2036-2040.
- 88) Lee CJ, Huie P, Leng T, Peterman M, Marmor MF, **Blumenkranz MS**, Bent SF, Fishman HA. Microcontact printing on human tissue for retinal cell transplantation. *Arch of Ophthalmol* 2002 Dec; 120(12):1714-8.
- 89) Moshfeghi DM, Kaiser PK, Grossniklaus HE, Sternberg P Jr, Sears JE, Johnson MW, Ratliff N, Branco A, **Blumenkranz MS**, Lewis H. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. *Am J Ophthalmol* 2003 Mar; 135(3):343-50.

**BIBLIOGRAPHY** (Continued)

- 90) Blinder KJ, **Blumenkranz MS**, Bressler NM, Bressler SB et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. *Ophthalmology* 2003 Apr; 110(4):667-73.
- 91) Miller JM, Palanker DV, Vankov A, Marmor MF, **Blumenkranz MS**. Precision and safety of the pulsed electron avalanche knife in vitreoretinal surgery. *Arch Ophthalmol* 2003 June; 121(6):871-877.
- 92) Shaikh S, Shaikh N, Chun SH, Spin JM, **Blumenkranz MS**, Marmor MF. Retinal evaluation of patients on chronic amiodarone therapy. *Retina* 2003 Jun; 23(3):354-359.
- 93) Peterman MC, Bloom DM, Lee C, Bent SF, Marmor MF, **Blumenkranz MS**, Fishman HA. Localized Neurotransmitter release for use in a prototype retinal interface. *Invest Ophthalmol Vis Sci* 2003 Jul; 44(7):3144-3149.
- 94) Mino De Kaspar H, Shriver EM, Nguyen EV, Egbert PR, Singh K, **Blumenkranz MS**, Ta CN. Risk factors for antibiotic-resistant conjunctival bacterial flora in patients undergoing intraocular surgery. *Graefes Arth Clin Exp Ophthalmol* Aug 2003 eArticle.
- 95) Ta CN, Chang RT, Singh K, Egbert PR, Shriver EM, **Blumenkranz MS**, Mino De Kaspar H. Antibiotic resistance patterns of ocular bacterial flora: A prospective study of patients undergoing anterior segment surgery. *Ophthalmology* 2003 Oct; 110(10):1946-51.
- 96) Peterman MC, Mehenti NZ, Bilbao KV, Lee CJ, Leng T, Noolandi J, Bent SF, **Blumenkranz MS**, Fishman HA. The artificial synapse chip: A flexible retinal interface based on directed retinal cell growth and neurotransmitter stimulation. *Artif Organs* 2003 Nov; 27(11):975-85.
- 97) Ta CN, Egbert PR, Singh K, **Blumenkranz MS**, Mino De Kaspar H. Preoperative Ofloxacin: Author reply. *Ophthalmology* 2003 Dec; 110(12):2431-2.
- 98) Gass JD, Sever RJ, Grizzard WS, Clarkson JG, **Blumenkranz MS**, Wind CA, Shurman R. Multifocal pigment epithelial detachments by reticulum cell sarcoma: A characteristic fundoscopic picture. 1984 [classical article] *Retina* 2003 Dec; 23(6 Suppl):135-143.
- 99) Palanker D, Huie P, Vankov A, Freyvert Y, Fishman H, Marmor MF, **Blumenkranz MS**. Attracting retinal cells to electrodes for high-resolution stimulation. *Ophthalmic Technologies*, vol.5314, SPIE (2004).
- 100) Ta CN, Egbert PR, Singh K, **Blumenkranz MS**, de Kaspar HM. The challenge of determining aqueous contamination rate in anterior segment intraocular surgery. *Am J Ophthalmol* 2004 Apr; 137(4):662-667.

**BIBLIOGRAPHY** (Continued)

- 101) Peterman MC, Noolandi J, **Blumenkranz MS**, Fishman HA. Fluid flow past an aperture in a microfluidic channel. *Anal Chem.* 2004 Apr; 76(7):1850-1856.
- 102) Lee CJ, **Blumenkranz MS**, Fishman HA, Bent SF. Controlling cell adhesion on human tissue by soft lithography. *Langmuir* 2004 May; 20(10):4255-41666.
- 103) Leng T, Miller JM, Bilbao KV, Palanker DV, Huie P, **Blumenkranz MS**. The chick chorioallantoic membrane (CAM) as a model tissue for surgical retinal research and simulation. *Retina* 2004 June; 24(3):427-434.
- 104) Peterman MC, Noolandi J, **Blumenkranz MS**, Fishman HA. Localized chemical release from an artificial synapse chip. *Proc Natl Acad Sci U S A.* 2004 Jul 6; 101(27):9951-4. Epub 2004 Jun 24.
- 105) De Kaspar HM, Chang RT, Shriver EM, Singh K, Egbert PR, **Blumenkranz MS**, Ta CN. Three-day application of topical ofloxacin reduces the contamination rate of microsurgical knives in cataract surgery: a prospective randomized study. *Ophthalmology* 2004 Jul; 111(7):1352-1355.
- 106) Palanker D, Huie P, Vankov A, Aramant R, Seiler M, Fishman H, Marmor M, **Blumenkranz MS**. Migration of Retinal Cells through a Perforated Membrane: Implications for a High-Resolution Prosthesis. *Invest Ophthalmol Vis Sci.* 2004 Sep; 45(9):3266-70.
- 107) Leng T, Wu P, Mehenti NZ, Bent SF, Marmor MF, **Blumenkranz MS**, Fishman HA. Directed retinal nerve cell growth for use in a retinal prosthesis interface. *Invest Ophthalmol Vis Sci.* 2004 Nov; 45(11):4132-7.
- 108) Mino de Kaspar H, Chang RT, Singh K, Egbert PR, **Blumenkranz MS**, Ta CN. Prospective randomized comparison of 2 different methods of 5% povidone-iodine applications for anterior segment intraocular surgery. *Arch Ophthalmol* 2005 Feb; 123(2):161-5.
- 109) **Blumenkranz MS**. New therapy for central retinal vein occlusion: are intravitreal steroids a possible answer? *Arch Ophthalmol* 2005 Feb; 123(2):259-61.
- 110) Mino de Kaspar H, Koss MJ, He L, **Blumenkranz MS**, Ta CN. Antibiotic susceptibility of preoperative normal conjunctival bacteria. *Am J Ophthalmol* 2005 Apr; 139(4):730-3.
- 111) Lee CJ, **Blumenkranz MS**, Fishman HA, Bent SF. Controlling cell adhesion on human tissue by soft lithography. *Langmuir* 2004 May 11; 20(10):4155-61.
- 112) Rosenfeld PJ, Schwartz SD, **Blumenkranz MS**, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. *Ophthalmology* 2005 Jun; 112(6):1048-53.

**BIBLIOGRAPHY** (Continued)

- 113) **Blumenkranz MS**, Yellachich D, Andersen DE, Wiltberger MW, Mordaunt D, et al. Semiautomated patterned scanning laser for retinal photocoagulation. *Retina* 2006 Mar; 26(3):370-6.
- 114) Lin RJ, **Blumenkranz MS**, Binkley J, Wu K, Vollrath D. A novel His158Arg mutation in TIMP3 causes a late-onset form of Sorsby Fundus Dystrophy. *Am J Ophthalmol* 2006 Nov; 142(5):839-48. Epub 2006 Sept. 20.
- 115) Koss MD, Eder M, **Blumenkranz MS**, Klauss V, Ta CN, de Kaspar HM. The effectiveness of the new fluoroquinolones against the normal bacterial flora of the conjunctiva. *Ophthalmologie* 2007 Jan; 104(1):21-7.
- 116) Kupperman BD, **Blumenkranz MS**, Haller JA, Williams GA et al. Randomized controlled study of an intravitreal dexamethasone drug delivery system in patients with persistent macular edema. *Arch Ophthalmol* 2007 Mar; 125(3):309-317.
- 117) Moshfeghi DM, **Blumenkranz MS**. Role of genetic factors and inflammation in age-related macular degeneration. *Retina* 2007 Mar; 27(3):269-275. Review
- 118) Ronan SM, Yoganathan P, Chien FY, Corcostegui IA, **Blumenkranz MS**, et al. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. *Retina*. 2007 Jun; 27(5):535-40.
- 119) **Blumenkranz MS**. The current status of lasers in treating diabetic retinopathy. *Retinal Physician* Sept 2007; 42-47.
- 120) Jain A, Egbert P, McCulley TJ, **Blumenkranz MS**, Moshfeghi DM. Endogenous scedosporium apiospermum endophthalmitis. *Arch Ophthalmol* 2007; (125):1286-9.
- 121) **Blumenkranz MS**. Current and future trends in the treatment of macular edema. *John Hopkins Advanced Studies in Ophthalmology* 2007 Dec; 4(7):187-190.
- 122) Jain A, **Blumenkranz MS**, Paulus Y, Wiltberger MW, Andersen DE, Huie P, Palanker D. Effects of pulse duration on size and character of the lesion in retinal photocoagulation. *Arch Ophthalmol* 2008 Jan; 126(1):78-85.
- 123) **Blumenkranz MS**. Ongoing studies of intraocular sustained-release drug delivery implants for macular edema. *Retinal Physician* 2008 Jan; 29-11.
- 124) De Caro JJ, Ta CN, Ho KH, Cabaal L, Hu N, Sanislo SR, **Blumenkranz MS**, Moshfeghi DM, Jack R, De Kaspar HM. Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections. *Retina* 2008 Jun; 28(6):877-883.

**BIBLIOGRAPHY** (Continued)

- 125) Wong LJ, Desai JR, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, **Blumenkranz MS**. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. *Retina* 2008 Oct 28(8):1151-8.
- 126) Zoumalan CI, **Blumenkranz MS**, McCulley TJ, Moshfeghi DM. Severe surfing-related ocular injuries: The Stanford-Northern California Experience. *Br J Sports Med* 2008; 42(10):555-7.
- 127) Paulus YM, Jain A, Gariano RF, Stanzel BV, Marmor M, **Blumenkranz MS**, Palanker D. Healing of retinal photocoagulation lesions. *Invest Ophthalmol Vis Sci* 2008 Dec; 49(12):5540-5.
- 128) Williams GA, Haller JA, Kupperman BD, **Blumenkranz MS** et al on behalf of The Dexamethasone DDS Phase II Study Group. Dexamethasone posterior-segment drug delivery system in treatment of macular edema resulting from uveitis or Irvine-Gass Syndrome. *Am J Ophthalmol* 2009 Jun; 147(6):1048-54.
- 129) Ip MS, Scott IU, VanVelhuisen PC, **Blumenkranz MS** et al on behalf of the SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol* 2009 Sep; 127(9):1101-1114.
- 130) Scott IU, Ip MS, VanVelhuisen PC, **Blumenkranz MS** et al on behalf of the SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. *Arch Ophthalmol* 2009 Sep; 127(9):1115-1128.
- 131) Chan A, **Blumenkranz MS**, Wu KH, Wang G et al. Photodynamic therapy with and without adjunctive intravitreal triamcinolone acetonide: A retrospective comparative study. *Ophthalmic Surg Lasers Imaging* 2009 Nov-Dec; (40(6):561-9.
- 132) **Blumenkranz MS**, "Optimal current and future treatments for diabetic macular oedema." *Eye (Lond)* 2010; 24(3):428-34.
- 133) de la Zerda A, Paulus YM, Teed R, Bodapati S, Dollberg Y, Khuri-Yakub BT, **Blumenkranz MS**, Moshfeghi DM, Gambhir SS. Photoacoustic ocular imaging. *Opt Lett*. 2010 Feb 1; 35(3):270-2.
- 134) Haller JA, Kuppermann BD, **Blumenkranz MS**, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreal dexamethasone drug delivery systems in patients with diabetic macular edema. *Arth Ophthalmol* 2010 Mar; 128(3):289-96.

**BIBLIOGRAPHY** (Continued)

- 135)Kuppermann BD, Chou C, Weinberg DV, Whitcup SM, Haller JA, **Blumenkranz MS**; Dexamethasone DDS Phase II Study Group. Intravitreal dexamethasone effects on different patterns of diabetic macular edema. *Arch Ophthalmol* 2010 May; 128(5):642-3.
- 136)Haller JA, Bandello F, Belfort R Jr, **Blumenkranz MS**, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. *Ophthalmology* 2010 Jun; 117(6):1134-1146.e3.
- 137)Palanker DV, **Blumenkranz MS**, Andersen D, Wiltberger M, Marcellino G, Gooding P, Angeley D, Schuele G, Woodley B, Simoneau M, Friedman NJ, Seibel B, Battle J, Feliz R, Talamo J, Culbertson W Femtosecond laser-assisted cataract surgery with integrated optical coherence tomography. *Sci Transl Med* 2010; 2(58):58ra85.
- 138)Leng T, **Blumenkranz MS**. Correspondence. *Retina* 2011 March.
- 139)**Blumenkranz MS**, Haller JA, Kuppermann BD, Williams GA, Ip M, Davis M, Weinberg DV, Chou C, Whitcup SM Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema. *Retina* 2010 Jul-Aug; 30(7):1090-4.
- 140)Palanker D, Lavinsky D, **Blumenkranz MS**, Marcellino G. The impact of pulse duration and burn grade on size of retinal photocoagulation lesion: implications for pattern density. *Retina* 2011; 31(8):1664-9.
- 141)He L, Chan A, Leng T, **Blumenkranz MS**. Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy. *Clin Ophthalmol* 2011; 5:751-8.
- 142)Palanker DV, **Blumenkranz MS**, Marmor MF. Fifty years of ophthalmic laser therapy. *Arch Ophthalmol* 2011; 129(12):1613-9.
- 143)Friedman NJ, Palanker DV, Schuele G, Andersen D, Marcellino G, Seibel BS, Battle J, Feliz R, Talamo JH, **Blumenkranz MS**, Culbertson WW. Femtosecond laser capsulotomy. *J Cataract Refract Surg* 2011; 3(7):1189-98:
- 144)Chan A, Leung LS, **Blumenkranz MS**. Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion. *Clin Ophthalmol* 2011; 5: 1043-9.

**BIBLIOGRAPHY** (Continued)

- 145) Dugel PU, **Blumenkranz MS**, Haller JA, Williams GA, Solley WA, Kleinman DM, Naor. A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. *Ophthalmology*. 2012 Jan;119(1):124-31.
- 146) Stanzel BV, **Blumenkranz MS**, Binder S, Marmor MF. Longterm cultures of the aged human RPE do not maintain epithelial morphology and high transepithelial resistance. *Graefes Arch Clin Exp Ophthalmol*. 2012 Feb;250(2):313-5.
- 147) Leung LS, Silva RA, **Blumenkranz MS**, Flynn HW Jr, Sanislo SR. Macular infarction following intravitreal bevacizumab for treatment of central retinal vein occlusion. *Ophthalmic Surg Lasers Imaging*. 2012 Jul 19;43
- 148) Nomoto H, Lavinsky D, Paulus YM, Leung LS, Dalal R, **Blumenkranz MS**, Palanker D. Effect of intravitreal triamcinolone acetonide on healing of retinal photocoagulation lesions. *Retina*. 2013 Jan;33(1):63-70.
- 149) Silva RA, Berrocal AM, Moshfeghi DM, **Blumenkranz MS**, Sanislo S, Davis JL. Herpes simplex virus type 2 mediated acute retinal necrosis in a pediatric population: case series and review. *Graefes Arch Clin Exp Ophthalmol*. 2013 Feb;251(2):559-66.
- 150) **Blumenkranz MS**. The evolution of laser therapy in ophthalmology: a perspective on the interactions between photons, patients, physicians, and physicists: the LXX Edward Jackson Memorial Lecture. *Am J Ophthalmol*. 2014 Jul;158(1):12-25.
- 151) Avery RL, Bakri SJ, **Blumenkranz MS**, Brucker AJ, Cunningham ET Jr, D'Amico DJ, Dugel PU, Flynn HW Jr, Freund KB, Haller JA, Jumper JM, Liebmann JM, McCannel CA, Mieler WF, Ta CN, Williams GA. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. *Retina*. 2014 Dec;34 Suppl 12:S1-S18.
- 152) He L, Silva RA, Moshfeghi DM, **Blumenkranz MS**, Leng T. Aflibercept for the treatment of Retinal Pigment Epithelial Detachments. *Retina*. 2015 Sep 21. [Epub ahead of print]
- 153) Rakoczy EP, Lai CM, Magno AL, Wikstrom ME, French MA, Pierce CM, Schwartz SD, **Blumenkranz MS**, Chalberg TW, Degli-Esposti MA, Constable IJ. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. *Lancet*. 2015 Sep 29. pii: S0140-6736(15)00345-1.
- 154) Myung D, Jais A, He L, **Blumenkranz MS**, Chang R, 3D Printed Smartphone Indirect Lens Adapter for Rapid, High Quality Retinal Imaging: *Journal of Mobile Technology in Medicine* 2014 Feb 28.

**BIBLIOGRAPHY** (Continued)

155)Rodrigues IA, Sprinkhuizen SM, Barthelmes D, **Blumenkranz MS**, Cheung G, Haller J, Johnston R, Kim R, Klaver C, McKibbin M, Ngah NF, Pershing S, Shankar D, Tamura H, Tufail A, Weng CY, Westborg I, Yelf C, Yoshimura N, Gillies MC. Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration, *Am J Ophthalmol*. 2016 Apr 27. pii: S0002-9394(16)30182-9. doi: 10.1016/j.ajo.2016.04.012. [Epub ahead of print]

156)Callaway NF, Ludwig CA, **Blumenkranz MS**, Jones JM, Fredrick DR, Moshfeghi DM. Retinal and Optic Nerve Hemorrhages in the Newborn Infant: One-Year Results of the Newborn Eye Screen Test Study. *Ophthalmology*. 2016 May;123(5):1043-52. doi: 10.1016/j.ophtha.2016.01.004. Epub 2016 Feb 11.

157)Toy BC, Myung DJ, He L, Pan CK, Chang RT, Polkinhorne A, Merrell D, Foster D, **Blumenkranz MS**. Smartphone-Based Dilated Fundus Photography and Near Visual Acuity Testing as Inexpensive Screening tools to Detect Referral Warranted Diabetic Eye Disease. *Retina*. 2016 May;36(5):1000-8. doi: 10.1097/IAE.0000000000000955.

158)Ludwig, C. A., Callaway, N. F., Fredrick, D. R., **Blumenkranz, MS**, Moshfeghi, D. M. What colour are newborns' eyes? Prevalence of iris colour in the Newborn Eye Screening Test (NEST) study *Acta Ophthalmologica*. 2016; 94 (5): 485-488

159)Constable, I. J., **Blumenkranz, MS**, Schwartz, S. D., Barone, S., Lai, C., Rakoczy, E. P. Gene Therapy for Age-Related Macular Degeneration. *Asia-Pacific journal of ophthalmology* (Philadelphia, Pa.) 2016; 5 (4): 300-303

160)Calloway, N. F., Ludwig, C. A., **Blumenkranz, MS**, Jones, J. M., Fredrick, D. R., Moshfeghi, D. M. Retinal and Optic Nerve Hemorrhages in the Newborn Infant: One-Year Results of the Newborn Eye Screen Test Study. *Ophthalmology*, 2016; doi:10.1016/j.ophtha.2016.01.004 123 (5): 1043-1052

161)Calloway, N. F., Ludwig, C. A., **Blumenkranz, MS** Jones, J. M., Fredrick, D. R., Moshfeghi, D. M. Retinal and Optic Nerve Hemorrhages in the Newborn Infant *Ophthalmology*. 2016; doi: 10.1016/j.ophtha.2016.01.004 123 (5): 1043-1052

162)Paulus, Y. M., Kuo, C., Morohoshi, K., Nugent, A., Zheng, L. L., Nomoto, H., **Blumenkranz, MS**, Palanker, D., Ono, S. J. Serum Inflammatory Markers After Rupture Retinal Laser Injury in Mice Ophthalmic Surgery Lasers & Imaging, *Retina* 2015; PMID: 25856824 46 (3): 362-368

163)Paulus YM, Leung LS, Pilyugina S, Blumenkranz MS. Comparison of Pneumatic Retinopexy and Scleral Buckle for Primary Rhegmatogenous Retinal Detachment Repair. *Ophthalmic Surg Lasers Imaging Retina*. 2017 Nov 1;48(11):887-893.

164)Kapur S, Silverman AP, Ye AZ, Papo N, Jindal D, Blumenkranz MS, Cochran JR. Engineered ligand-based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis. *Bioeng Transl Med*. 2017 Mar;2(1):81-91. doi: 10.1002/btm2.10051. Epub 2017 Feb 17.

165)Blumenkranz MS, Tarver ME, Myung D, Eydelman MB, Collaborative Community on Ophthalmic Imaging Executive Committee. The Collaborative Community on Ophthalmic Imaging: Accelerating Global Innovation and Clinical Utility. *Ophthalmology*. 2022 Feb, 129(2)e9-e13

165) Constable IJ, Lai CM, Magno AL, French MA, Barone SB, Schwartz SD, Blumenkranz MS, Degli-Esposti MA, Rakoczy EP. Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial. *Am J Ophthalmol.* 2017 May;177:150-158. doi: 10.1016/j.ajo.2017.02.018. Epub 2017 Feb 27.

166) Rakoczy EP, Magno AL, Lai CM, Pierce CM, Degli-Esposti MA, **Blumenkranz MS, Constable IJ.** Three-year follow-up of Phase 1 and 2a rAAV.sFLT-1 subretinal gene therapy trials for exudative age related macular degeneration. *Am J Ophthalmol.* 2019 Mar 13. pii: S0002-9394(19)30104-7.. [Epub ahead of print]

### **COLLABORATIVE RESEARCH (Partial List -2002)**

- 2) **Blumenkranz MS** as part of the Macular Photocoagulation Study Group. The use of fundus photographs and fluorescein angiograms in the identification and treatment of choroidal neovascularization in the macular photocoagulation study. *Ophthalmology* 1989; 96:1526-1534.
- 3) **Blumenkranz MS** as part of the Macular Photocoagulation Study Group. Argon Laser Photocoagulation for Neovascular Maculopathy. Five-Year Results from Randomized Clinical Trials. *Arch Ophthalmol* 1991; 109:1109-1114.
- 4) **Blumenkranz MS** as part of the Macular Photocoagulation Study Group. Laser Photocoagulation of Subfoveal Neovascular Lesions in Age-Related Macular Degeneration. Results of a Randomized Clinical Trial. *Arch Ophthalmol* 1991; 109:1220-1231.
- 5) **Blumenkranz MS** as part of the Macular Photocoagulation Study Group. Laser Photocoagulation of Subfoveal Recurrent Neovascular Lesions in Age-Related Macular Degeneration. Results of a Randomized Clinical Trial. *Arch Ophthalmol* 1991; 109:1232-1241.
- 6) **Blumenkranz MS** as part of the Macular Photocoagulation Study Group. Subfoveal Neovascular Lesions in Age-Related Macular Degeneration. Guidelines for Evaluation and Treatment in the Macular Photocoagulation Study. *Arch Ophthalmol* 1991; 109:1242-1257.
- 7) **Blumenkranz MS** as part of the Silicone Study Group. Vitrectomy with Silicone Oil or Perfluoropropane Gas in Eyes with Severe Proliferative Vitreoretinopathy: Results of a Randomized Clinical Trial. Silicone Study Report 2. *Arch Ophthalmol* 1992; 110:780-792.
- 8) **Blumenkranz MS** as part of the Silicone Study Group. Vitrectomy With Silicone Oil or Sulfur Hexafluoride Gas in Eyes with Severe Proliferative Vitreoretinopathy: Results of a Randomized Clinical Trial. Silicone Study Report 1. *Arch Ophthalmol* 1993; 110:770-779.
- 9) **Blumenkranz MS** as part of the Silicone Study Group. Tap Study Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials—TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. *Arch Ophthalmol* 1999; 117:1329-45 (Member of Writing Committee.)

- 9) **Blumenkranz MS** as part of the Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Verteporfin in photodynamic therapy report 2. *Am J Ophthalmol* 2001; 131(5):541-60 (Member of Writing Committee)
- 10) **Blumenkranz MS** as part of the Verteporfin In Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with Verteporfin. 1-year results of a randomized clinical trial. VIP report no. 1. *Ophthalmology* 2001; 108(5):841-52. (Member of Writing Committee)
- 11) **Blumenkranz MS** as part of the TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trial-tap report 2. *Arch of Ophthalmol* 2001; 119(2):198-207.
- 12) Bressler NM, Arnold J, Benchaboune M, **Blumenkranz MS**, et al. Verteporfin therapy of Subfoveal choroidal neovascularization in patients with age-related macular degeneration: Additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. *Arch Ophthalmol* 2002 Nov; 120(11):1443-54.

#### **BOOK CHAPTERS**

1. Culbertson WW, **Blumenkranz MS**. The acute retinal necrosis syndrome. In: Blodi FC, Ed. Herpes Simplex Infection of the Eye. New York, Churchill Livingstone, pp. 77-89, 1984
2. **Blumenkranz MS**, Culbertson WW. Chorioretinal biopsy: Description of the technique. In Ryan SJ, Proceedings of the International Symposium on Retinal Disease, Grune and Stratton, 1985.
3. **Blumenkranz MS**, Hartzler M, Gardner T. Fluid gas exchange after vitrectomy; Clinical and biochemical considerations in modern concepts in vitreoretinal disease. Ed. Adolph Neetens, M.D., Ph.D. University of Antwerp, UIA Press, Antwerp, Belgium, 1986. pp 257-259.
4. Blankenship GW, Friedland BR, **Blumenkranz MS**. Ocular effects and clearance of intravitreal 5-fluorouracil. Eds. George Blankenship, M.D., M. Stirpe, M.D., S. Binder, Liviana Press, Basic and Advanced Vitreous Surgery, 415-419, 1986.
5. **Blumenkranz MS**. Management of complicated retinal detachment. Retinal Diseases. Ed. Mark Tso, M.D., J.B. Lippincott Co., 1988.

6. Hartzler MK, **Blumenkranz MS**. Fluoropyrimidines for treatment of PVR and glaucoma filtration surgery. *Retinal Diseases*. Ed. Mark Tso, M.D. J.B. Lippincott. New York, New York. 1988.
7. **Blumenkranz MS**. Complications and postoperative management. Ed. Packer AJ. *Manual of Retinal Surgery*. Churchill Livingstone. New York, New York 1989 (Revised 2000).
8. **Blumenkranz MS**, Hartzler MK, Alvira G. Effect of heparin on cell-mediated contraction and proliferation of human retinal pigment epithelial cells and ocular fibroblasts. *Proliferative Vitreoretinopathy*. Eds. K. Heimann, P. Wiedemann. Kaden and Verlag, Heidelberg, Federal Republic of Germany, pp 251-256, 1989.
9. Alvira G, Hartzler M, **Blumenkranz MS**, Camacho H. Heparin, a possible new approach to the treatment of proliferative vitreoretinopathy. *Proliferative Vitreoretinopathy*. Eds. K. Heimann, P. Wiedemann. Kaden and Verlag, Heidelberg, Federal Republic of Germany, pp 268-271, 1989.
10. **Blumenkranz MS**, Verstraeten TC. Fluorescein angiography as an aid in the diagnosis and treatment of infectious and inflammatory diseases of the retina and choroid. Eds. W. Tasman, E. Jaeger. *Foundations of Clinical Ophthalmology*. J.B. Lippincott Company. 113-E, pp 1-22.
11. **Blumenkranz MS**, Maguire AM. Modern management considerations in dislocation of crystalline and intraocular lenses. *Proceedings of the 3<sup>rd</sup> International Congress on Vitreoretinal Surgery*, G.B. Bietti Foundation, Rome, Morrison Communications 1992.
12. **Blumenkranz MS**, Hartzler MK, Iverson D. An overview of potential heparin applications in vitreoretinal surgery. *Proceedings of the 3<sup>rd</sup> International Congress on Vitreoretinal Surgery*, G.B. Bietti Foundation, Rome, Italy, September 1991.
13. William GA, **Blumenkranz MS**. Vitreous Humor Section, "Pathophysiologic Mechanisms in Vitreous Disease". *Duane's Clinical Ophthalmology*. Eds. Wm. Tasman, M.D., Jaeger, M.D. J.B. Lippincott Company, 1992.
14. **Blumenkranz MS**, Penneys NS. Acquired immunodeficiency syndrome and the eye. *Dermatology Clinics of North America*. 1992; 10:777-83.
15. **Blumenkranz MS**. Acute Retinal Necrosis. Eds. Fraunfelder F, Roy FH. *Current Ocular Therapy*, 4<sup>th</sup> Ed. W.B. Saunders Co., 1994 (Revised 1999).
16. **Blumenkranz MS**, Duker J, D'Amico, DJ. Acute retinal necrosis in principles and practice of ophthalmology. Eds Albert D, Jacobiec F, W. B. Saunders Company, pp 945-962, 1994 (Revised 1999).
17. **Blumenkranz MS**, Hartzler MK. The mechanism of action of drugs for the treatment of vitreoretinal scarring. In *Retina*, Vol. 3, *Surgical Retina*. Eds. Ryan S, Glaser B. *Retinal Diseases*. CV Mosby, pp 2281-2293, 1994 (Revised 2000).

18. **Blumenkranz MS**. Editor in Chief, Ai E, Irvine A Co-Editors. Age-related macular degeneration: Vision for the future. (CD -ROM) Vitreoretinal Interfaces, Zweng Memorial Research Foundation, Menlo Park CA, 1994.
19. Brouman ND, **Blumenkranz MS**. Macular edema in pseudophakic patients with nonproliferative diabetic retinopathy. Proceedings of the 5<sup>th</sup> International Congress on Vitreoretinal Surgery, G.B. Bietti Foundation, Rome, Italy, September 1997.
20. **Blumenkranz MS**. Lens sparing treatment of recurrent diabetic vitreous hemorrhage associated with anterior neovascularization by silicone oil injection, cryopexy, and laser photocoagulation. Proceedings of the 5<sup>th</sup> International congress on Vitreoretinal Surgery, G.B. Bietti Foundation, Rome, Italy, September 1997.
21. Brouman ND, **Blumenkranz MS**. Fungal Diseases. In: Retina-Vitreous-Macula, Vol 1. Guyer, Yannuzzi, Chang, Shields and Green. W.B. Saunders Co., pp 772-792, 1998.
22. **Blumenkranz MS**, Woodburn KW. Photodynamic Therapy. In: Age-Related Macular Degeneration. Ed Jenifer I. Lim. Marcel Dekker Inc., pp 203-223, 2002.
23. Molnar FE, **Blumenkranz MS**. Pigment Epithelial Transplant of the Retina. In: Degeneracion Macular Asociada a la Edad: Eds Mones J, Gomez Ulla F. Prous Science, pp 331-342, 2005.
24. Palanker D, **Blumenkranz MS**, Weiter JJ. Retinal Laser Therapy: Biophysical basis and applications. In Retina, Vol. 1. Eds. Ryan S, Hinton DR. Basic Science and Inherited Retinal Diseases 4<sup>th</sup> Edition. Elsevier Mosby, pp 539-553, 2006.
25. **Blumenkranz MS**, Moshfeghi DM. Pharmacotherapy of Age-Related Macular Degeneration. In Retina, Vol. II. Eds. Ryan S, Schachat AP. Medical Retina 4<sup>th</sup> Edition. Elsevier Mosby, 2006.
26. **Blumenkranz MS**, Hartzler MK. The mechanism of action of drugs for the treatment of vitreoretinal scarring. In Retina, Vol. III, Surgical Retina. Eds. Ryan S, Wilkinson CP. Retinal Diseases 4<sup>th</sup> Edition. Elsevier Mosby, pp 2241-2253, 2006.

**PUBLISHED ABSTRACTS (Partial List 1978-2011)**

1. **Blumenkranz MS**, Susal A, Egbert PR. Orbital artifacts in clinical ultrasonography. Proceedings of American Institute of Ultrasound in Medicine 1978; 1:44.
2. **Blumenkranz MS**, Ophir A, Claflin A. A pharmacologic approach to non-neoplastic intraocular proliferation. *Invest Ophthalmol Vis Sci* (Suppl) 1981; 20:200.
3. Ophir A, **Blumenkranz MS**, Claflin A. A new model of intraocular proliferation. *Invest Ophthalmol Vis Sci* (Suppl) 1982; 20:235.

**PUBLISHED ABSTRACTS (Continued)**

4. Levada A, **Blumenkranz MS**. Biometric alterations in the globe following scleral buckling. *Invest Ophthalmol Vis Sci* (Suppl) 1982; 22:53.
5. Meiler WF, **Blumenkranz MS**. Long-term vein occlusion: risk factors, status of the fellow eye. *Invest Ophthalmol Vis Sci* (Suppl) 1982; 22:69.
6. Hajek AS, **Blumenkranz MS**, Ringler S. Dichotomous effect of glucocorticosteroids on cells. *Invest Ophthalmol Vis Sci* (Suppl) 1982; 22:182.
7. Hernandez E, **Blumenkranz MS**. 5 Fluorouracil for the treatment of periretinal proliferation. *Invest Ophthalmol Vis Sci* (Suppl) 1982; 22:233.
8. Friedland B, **Blumenkranz MS**, Jarus G, Pressman B, Ward T. A new chromatographic technique for the determination of intraocular Fluorouracil (5-FU). *Invest Ophthalmol Vis Sci* (Suppl) 1983; 24:151.
9. Moffat K, **Blumenkranz MS**, Hernandez E, Schoch L. The influence of the lens capsule in vitreous surgery. *Invest Ophthalmol Vis Sci* (Suppl) 1983; 24:240.
10. **Blumenkranz MS**, Hajek A. Cellular mechanisms in the treatment of human intraocular proliferative disorders. *Invest Ophthalmol Vis Sci* (Suppl) 1983; 24:241.
11. Bastek J, **Blumenkranz MS**, O'Grady G, Parel J-M. Histopathologic characterization of the intraocular chorioretinal adhesion in the rabbit. *Invest Ophthalmol Vis Sci* (Suppl) 1983; 24:255.
12. Olsen K, **Blumenkranz MS**, Luttly G. Pathology responses of the iris vasculature. *Invest Ophthalmol Vis Sci* (Suppl) 1983; 24:285.
13. Jarus G, **Blumenkranz MS**, Hernandez E. The pharmacokinetics of intravitreal 5-Fluorouracil. *Invest Ophthalmol Vis Sci* (Suppl) 1983; 24:292.
14. Hernandez E, **Blumenkranz MS**. Further observations on experimental rubeosis iridis and its treatment. *Invest Ophthalmol Vis Sci* (Suppl) 1984; 24:112.
15. Mein C, **Blumenkranz MS**. Antiproliferative agents in traumatic detachment. *Invest Ophthalmol Vis Sci* (Suppl) 1984; 22:234.
16. Forster R, Hofling A, Brush L, Farah M, **Blumenkranz MS**. Antifungal activity of 5-Fluorouracil. *Invest Ophthalmol Vis Sci* (Suppl) 1984; 25:20.
17. Woodlief NF, **Blumenkranz MS**, Hernandez E, Sossi N. Extended delivery of therapeutic levels of intravitreal 5-FU. *Invest Ophthalmol Vis Sci* (Suppl) 1984; 25:272.

18. Olsen KR, **Blumenkranz MS**, Hernandez E, Hajek A. 5-Fluorouracil in the treatment of Greene's melanoma. *Invest Ophthalmol Vis Sci (Suppl)* 1984; 25:110.
19. Culotta FJ, **Blumenkranz MS**, Hernandez E, Farah M. Effect of neodymium:YAG laser lens capsulotomy on rubeosis iridis. *Invest Ophthalmol Vis Sci (Suppl)* 1984; 25:246.
20. Farah ME, **Blumenkranz MS**, Hernandez E. Histopathology of argon laser endophotocoagulation in rabbits. *Invest Ophthalmol Vis Sci (Suppl)* 1984; 25:334.
21. **Blumenkranz MS**, Hajek A, Sossi N, Sossi G. Evidence of cell specificity in proliferative vitreoretinopathy. *Invest Ophthalmol Vis Sci (Suppl)* 1984; 25:272.
22. Hartzler MK, **Blumenkranz MS**, Hajek A. The effects of fluoropyrimidines on collagen synthesis and collagen matrix contraction by human fibroblasts. *Invest Ophthalmol Vis Sci (Suppl)* 1985; 26:19.
23. Dalma J, **Blumenkranz MS**, Hernandez E. Variations in normal and post vitrectomy aqueous and vitreous cyclic nucleotide levels. *Invest Ophthalmol Vis Sci (Suppl)* 1985; 26:19.
24. Hernandez E, **Blumenkranz MS**, Hartzler MK, Rubin R. Two-dimensional electrophoresis of normal human aqueous and intraocular fluid from PVR patients. *Invest Ophthalmol Vis Sci (Suppl)* 1985; 26:19.
25. Richmond P, **Blumenkranz MS**, Jaffe M. Incidence and management of vitreous loss; changing patterns in cataract surgery. *Invest Ophthalmol Vis Sci (Suppl)* 1985; 26:123.
26. Blumenkranz MS, Hajek A, Hernandez E, Hartzler MK. Fluorouridine: a second generation ocular antimetabolite. *Invest Ophthalmol Vis Sci (Suppl)* 1985; 26:285.
27. Hartzler MK, **Blumenkranz MS**, Hajek A, Alvira G. Time dependence of fluoropyrimidine effects on cellular proliferation. *Invest Ophthalmol Vis Sci (Suppl)* 1986; 27:187.
28. Huang D, **Blumenkranz MS**, Hernandez E, Hartzler MK. The pharmacokinetics of intraocular and periocular 5-fluorouridine. *Invest Ophthalmol Vis Sci (Suppl)* 1986; 27:304.
29. Alvira G, Hartzler MK, **Blumenkranz MS**. Heparin inhibits cell-mediated collagen gel contraction. *Invest Ophthalmol Vis Sci (Suppl)* 1986; 27:305.
30. Hartzler MK, Daily W, **Blumenkranz MS**. Ocular pharmacology of the fluoropyrimidines; mechanism of action of 5-fluorouracil. *Invest Ophthalmol Vis Sci (Suppl)* 1987; 28:75.
31. Trese MT, Li-Ren L, **Blumenkranz MS**, Hartzler MK, Frank R, Mancini M. Cell biology of retinopathy of prematurity. *Invest Ophthalmol Vis Sci (Suppl)* 1987; 28:7.
32. Suchomel J, **Blumenkranz MS**. Pressure volume relationships in the gas-filled eye. *Invest Ophthalmol Vis Sci (Suppl)* 1987; 28:290.

33. Hartzler MK, **Blumenkranz MS**. Proliferative and contractile effects of thrombin in vitro. *Invest Ophthalmol Vis Sci (Suppl)* 1988; 29:222.
34. Ward T, Hartzler MK, **Blumenkranz MS**. Comparison of intravitreal 5-fluorouridine and 5-fluorouracil in a rabbit model of proliferative vitreoretinopathy. *Invest Ophthalmol Vis Sci (Suppl)* 1988; 29:304.
35. Rockwell D, **Blumenkranz MS**, Margherio RR. Gender dependence of macular holes. *Invest Ophthalmol Vis Sci (Suppl)* 1988; 29:121.
36. Iverson DA, Katsura H, Hartzler MK, Chung M, **Blumenkranz MS**. Inhibition of fibrin formation following vitrectomy in the rabbit by infusion low molecular weight heparin. *Invest Ophthalmol Vis Sci (Suppl)* 1989; 30:273.
37. Hartzler MK, Dailey W, Iverson DA, **Blumenkranz MS**. Analysis of intraocular fluid from patients with proliferative retinopathies. *Invest Ophthalmol Vis Sci (Suppl)* 1989; 30:12.
38. Katsura H, Hartzler MK, **Blumenkranz MS**. Two-dimensional gel electrophoresis of normal and diseased human vitreous soluble protein. *Invest Ophthalmol Vis Sci (Suppl)* 1989; 30:11.
39. **Blumenkranz MS**, Hartzler MK. The effects of low molecular weight heparin fractions on cell-mediated contraction and cellular proliferation. *Invest Ophthalmol Vis Sci (Suppl)* 1989; 30:13.
40. Bradford JD, Hartzler MK, Katsura H, Margherio AR, **Blumenkranz MS**. Light damage thresholds for retinal pigment epithelium are decreased by Chlorpromazine and Chloroquine. *Invest Ophthalmol Vis Sci (Suppl)* 1989; 30:463.
41. Katsura H, Hartzler MK, **Blumenkranz MS**. Affinity chromatography of human vitreous soluble protein: Comparison of serum and non-serum fractions and effects on cellular proliferation. Submitted. *Invest Ophthalmol Vis Sci (Suppl)* 1990.
42. Iverson D, Dailey W, Hartzler M, Chapman C, **Blumenkranz MS**. The effect of low molecular weight heparin on the mitogenicity of intraocular fluid from patients with proliferative retinopathies. *Invest Ophthalmol Vis Sci (Suppl)* 1991; 32:879.
43. Verstraeten T, Hartzler M, **Blumenkranz MS**. Use of lipophilic prodrug-linked 5FU in silicone oil for a sustained release system. *Invest Ophthalmol Vis Sci (Suppl)* 1991; 32:1047.
44. Minelli E, Hartzler M, **Blumenkranz MS**. Increased retinal epithelial cell toxicity following low level near UV irradiation. *Invest Ophthalmol Vis Sci (Suppl)* 1991; 32:1097.
45. Hartzler M, Bradford D, Dailey W, Dinda S, Cheng M, Minelli E, Bar S, **Blumenkranz MS**. In vitro effects of antioxidants in the drug-light interaction associated with pigmentary retinopathies. *Invest Ophthalmol Vis Sci (Suppl)* 1991; 32:1100.

46. Assil KK, Hartzler M, Weinreb RN, Nehorayan M, Ward T, **Blumenkranz MS**. Liposome suppression of proliferative vitreoretinopathy. *Invest Ophthalmol Vis Sci (Suppl)* 1991; 32:2891-2897.
- 47.
48. Innocenzi R, Glazer L, Stec M, Hartzler M, Iverson D, **Blumenkranz MS**. Treatment of experimental proliferative vitreoretinopathy in the rabbit with low molecular weight heparin. *Invest Ophthalmol Vis Sci (Suppl)* 1993; 34:950.
49. Iverson D, Miller T, Das A, Hartzler M, Chapman C, Innocenzi R, **Blumenkranz MS**. Histologic analysis of ocular tissue from an animal model of proliferative vitreoretinopathy. *Invest Ophthalmol Vis Sci (Suppl)* 1993; 34:1040.
50. Chapman C, Benner J, Chu T, **Blumenkranz MS**, Morse L. Subretinal hemorrhages in diabetic retinopathy. *Invest Ophthalmol Vis Sci (Suppl)* 1993; 34:1180.
51. Dinda S, Cheng M, Lin LR, Reddy V, Hartzler M, **Blumenkranz MS**. DNA damage in cells treated with phenothiazines and UV light. *Invest Ophthalmol Vis Sci (Suppl)* 1993; 34:1435.
52. Kahle EJ, Glazer LC, **Blumenkranz MS**, Orgel IK. Angiographic and clinical features of occult choroidal neovascularization in patients with pseudophakic cystoid macular edema. *Invest Ophthalmol Vis Sci (Suppl)* 1995; 36(4):1065.
53. Kim SY, Sanislo SR, Dalal R, Kelsoe WE, **Blumenkranz MS**. The selective effect of micropulse diode laser upon the retina. *Invest Ophthalmol Vis Sci (Suppl)* 1996; 37(3):3584.
54. Quiroz-Mercado H, Martinez JJ, D'Amico DJ, **Blumenkranz MS**, Marcellino G, Hmelar M. High repetition rate erbium:Yag laser (200 Hz) for vitreoretinal surgery. *Invest Ophthalmol Vis Sci (Suppl)* 1997; 38(4):408.
55. Humayun MU, **Blumenkranz MS**, Lewis H. Management of submacular hemorrhage associated with retinal arterial macroaneurysms. *Invest Ophthalmol Vis Sci (Suppl)* 1997; 38(4):3083.
56. **Blumenkranz MS**, Woodburn K. Lutetium texaphyrin angiography: A new method for the evaluation and treatment of retinal and choroidal vascular disorders. *Invest Ophthalmol Vis Sci (Suppl)* 1998; 39(4):2142.
57. Palanker D, **Blumenkranz MS**. Electrical plasma-mediated dissector for vitreoretinal surgery. *Invest Ophthalmol Vis Sci (Suppl)* 1999; 40(4):4997.
58. **Blumenkranz MS**, Miller JW, Guyer DR, Slakter JS, Sickenberg M, Zilliox P, Jerdan J. Preliminary results from a Phase I dose-response study of photodynamic therapy with motexafin lutetium (Lu-Tex) to treat subfoveal CNV. *Invest Ophthalmol Vis Sci (Suppl)* 2000; 40(4):2827.

**PUBLISHED ABSTRACTS (Continued)**

59. Sanislo SR, Palanker DV, Miller J, Marmor MF, Huie P, Vankov A, Branco A, **Blumenkranz MS**. Evaluation of toxicity in vitreoretinal applications of the pulsed electron avalanche knife (PEAK). *Invest Ophthalmol Vis Sci (Suppl)* 2001; 42(4):2312.
60. Palanker D, Miller J, Marmor M, Sanislo S, Huie P, **Blumenkranz MS**. Pulsed Electron Avalanche Knife (PEAK) for Intraocular Surgery. *Invest Ophthalmol Vis Sci* 2001; 42:2673.
61. **Blumenkranz MS**, Palanker DV, Fletcher D, Miller J. A pulsed liquid microjet for ocular microsurgical applications. *Invest Ophthalmol Vis Sci (Suppl)* 2001; 42(4):3858.
62. Lin DY, **Blumenkranz MS**, Brothers R. Digital Diabetic Screening Group (DDSG). The role of digital fundus photography in diabetic retinopathy screening. *Invest Ophthalmol Vis Sci (Suppl)* 2001; 42(4):4333.
63. Braun M, de Kaspar H, Ta CN, Egbert P, Singh K, **Blumenkranz MS**. Immediate bacterial contamination of the aqueous humor in intraocular surgery. *Invest Ophthalmol Vis Sci (Suppl)* 2001; 42(4):1384.
64. Branco A, **Blumenkranz MS**, Miller J, Slakter J, Sanislo S, Woodburn K, Rowe T, Simpson G. Photodynamic angiography: A new technique utilizing Lutex. *Invest Ophthalmol Vis Sci (Suppl)* 2001; 42(4):2757.
65. Ta CN, Mino de Kaspar H, Chang RT, Egbert PR, Singh K, **Blumenkranz MS**. Antibiotic susceptibility pattern of coagulase-negative staphylococci in patients undergoing intraocular surgery. *Invest Ophthalmol Vis Sci (Suppl)* 2001; 42(4):1375.
66. Schwartz SD, **Blumenkranz MS**, Rosenfeld PJ, Miller JW, Haller J, Fish G, Lobes L, Singerman L, Greene WI, Reimann J. Safety of rhuFab V2, an anti-VEGF antibody fragment, as a single intravitreal injection in subjects with neovascular age-related macular degeneration. *Invest Ophthalmol Vis Sci (Suppl)* 2001; 42(4):2807.
67. Palanker D, Miller J, Marmor M, Huie P, Vankov A, **Blumenkranz MS**. Evaluation of precision and safety of the pulsed electron avalanche knife (PEAK) in vitreoretinal surgery. *Invest Ophthalmol Vis Sci (Suppl)* 2001; 42(4):3859.
68. Huie P, Peterman MC, Leng T, Lee CJ, Marmor MF, Bloom DM, **Blumenkranz MS**, Fishman HA. Tissue-engineered neurite conduits to connect retinal ganglion cells to an electronic retinal prosthesis. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 4475.
69. Leng T, Huie P, Mehenti NZ, Peterman MC, Lee CJ, Marmor MF, Sanislo SR, **Blumenkranz MS**, Fishman HA. Directed ganglion growth and stimulation with microcontact printing as a prototype visual prosthesis interface. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 4454.

**PUBLISHED ABSTRACTS (Continued)**

70. Ta CN, de Kaspar HM, Chang RT, Shriver EM, Egbert PR, Singh K, **Blumenkranz MS**. Antibiotic susceptibility pattern of coagulase-negative staphylococci in patients undergoing intraocular surgery. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 4444.
71. Lin DY, **Blumenkranz MS**, Brothers RJ, Grosvenor DM. Prevalence of diabetic retinopathy in an urban diabetic population based on a single-field nonmydriatic digital fundus photographic screening modality. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 3528.
72. Sanislo SR, **Blumenkranz MS**, Vankov A, Palanker DV. A new pulsed liquid microjet for potential treatment of retinal vascular occlusions. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 3528.
73. Fung AE, Lee CJ, Leng T, Bilbao LV, Peterman MC, **Blumenkranz MS**, Bent SF, Fishman, HA. Tissue engineered lens capsule as a substrate for IPE and RPE transplantation. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 3452.
74. Bilbao KV, Leng T, Fung AE, Huie P, Sanislo SR, Marmor MF, **Blumenkranz MS**, Fishman HA. A biodegradable matrix facilitates the use of lens capsule as a substrate for subretinal cell transplantation. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 3441.
75. Shriver EM, Ta CN, Egbert PR, Singh K, Chang RT, **Blumenkranz MS**, de Kaspar HM. Multiresistant *Staphylococcus epidermidis* on the conjunctiva prior to intraocular surgery. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 3074.
76. **Blumenkranz MS**, Quiroz-Mercado H, Sanislo SR, Garcia G, Dubnack S, Palanker DV. The Pulsed Electron Avalanche Knife (PEAK™) for intraocular surgery in patients with proliferative vitreoretinal disorders. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 3002.
77. Fishman HA, Peterman MC, Leng T, Huie P, Lee CJ, Bloom DM, Sanislo SR, Marmor MF, Bent SF, **Blumenkranz MS**. The artificial synapse chip: A novel interface for a retinal prosthesis based on neurotransmitter stimulation and nerve regeneration. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 2846.
78. Palanker DV, Vankov A, Huie P, **Blumenkranz MS**. A plasma-mediated cutter for anterior segment surgery. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 1941.
79. Quiroz-Mercado H, **Blumenkranz MS**, Palanker DV, Sanislo SR, Garcia-Aguirre G, Magdalenic R, Araya-Munoz CE, Ruiz M. Surgical therapy of central retinal vein occlusion by creation of choroidal retinal anastomosis. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 1872.

80. Miller J, Castelo-Branco A, Huie P, Sanislo S, **Blumenkranz MS**, Palanker DV. Application of the pulsed electron avalanche knife (PEAK™) to treatment of retinal vascular occlusions. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 1870.
81. Palanker DV, Vankov A, Huie P, **Blumenkranz MS**. A plasma-mediated cutter for anterior segment surgery. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 1941.
82. Chang RT, Ta, CN, Egbert PR, Singh K, Haw WW, Shriver EM, Espinosa L, Williams DY, **Blumenkranz MS**, Bacterial contamination of paracentesis blades used in cataract surgery. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 363.
83. **Blumenkranz MS**, Quiroz-Mercado H, Sanislo SR, Garcia G, Dubnack S, Palanker DV. The pulsed electron avalanche knife (PEAK) for intraocular surgery in patients with proliferative vitreoretinal disorders. *Invest Ophthalmol Vis Sci* 2002; 43:ARVO E-Abstract 3002.
84. Leng T, Huie P, Bilbao KV, **Blumenkranz MS**, Loftus DJ, Fishman HA. Carbon nanotube bucky paper as an artificial support membrane and Bruch's membrane patch in subretinal RPE and IPE transplantation. *Invest Ophthalmol Vis Sci* 2003; 44:ARVO E-Abstract 481.
85. Lee CJ, Bent SF, **Blumenkranz MS**, Fishman HA. RPE cell adhesion on spatially patterned lens capsule. *Invest Ophthalmol Vis Sci* 2003; 44:ARVO E-Abstract 501.
86. De Kaspar HM, Singh G, Egbert PR, Haw WW, Nguyen EV, Singh K, **Blumenkranz MS**, Ta CN. Ten-fold reduction of conjunctival bacterial contamination rate using a combined 3-day application of topical Ofloxacin and Iodine irrigation in patients undergoing anterior segment intraocular surgery. *Invest Ophthalmol Vis Sci* 2003; 44:ARVO E-Abstract 1457.
87. **Blumenkranz MS**, Palanker D, Sanislo SR, Marmor MH, Quiroz-Mercado H, Koch F, Kampik A, Miesner H, Amend P. The pulsed electron avalanche knife in human vitreoretinal surgery; a status report. *Invest Ophthalmol Vis Sci* 2003; 44:ARVO E-Abstract 3027.
88. Kuppermann BD, **Blumenkranz MS**, Haller JA, Williams GA, and Posurdex Study Group. An intravitreal Dexamethasone biorodible drug delivery system for the treatment of persistent diabetic macular edema. *Invest Ophthalmol Vis Sci* 2003; 44:ARVO E-Abstract 4289.
89. Williams GA, **Blumenkranz MS**, Haller JA, Kuppermann BD and Posurdex Study Group. Treatment of persistent macular edema (PME) associated with uveitis or Irvine-Gas Syndrome (IGS) with an intravitreal biorodible sustained Dexamethasone release implant; a prospective controlled multi-center clinical trial. *Invest Ophthalmol Vis Sci* 2003; 44:ARVO E-Abstract 4309.
90. Haller JA, **Blumenkranz MS**, Williams GA, Kuppermann BD and Posurdex Study Group. Treatment of persistent macular edema associated with central and branch retinal vein occlusion with extended delivery of intravitreal Dexamethasone. *Invest Ophthalmol Vis Sci* 2003; 44:ARVO E-Abstract 4311.

**PUBLISHED ABSTRACTS (Continued)**

91. Sanislo SR, Palanker D, Vankov A, Bilbao K, Marmor M, **Blumenkranz MS**. Bubble-free plasma blade for posterior segment surgery. *Invest Ophthalmol Vis Sci* 2003; 44:ARVO E-Abstract 4877.
92. Wu P, Mehenti NZ, Leng T, Marmor MF, **Blumenkranz MS**, Fishman HA. Cell demographics from full thickness retinal explant growth on micropatterned surfaces. *Invest Ophthalmol Vis Sci* 2003; 44: ARVO E-Abstract 5008.
93. Moshfeghi DM, **Blumenkranz MS**, Sanislo SS, Hnik P. Quantitative Verteporfin angiography in humans. *Invest Ophthalmol Vis Sci* 2003; 44:ARVO E-Abstract 5040.
94. Huie, P, Palanker D, Vankov A, Fishman HA, Marmor MF, **Blumenkranz MS**. Perforated membrane as an interface for focal electrical stimulation of retina. *Invest Ophthalmol Vis Sci* 2003; 44:ARVO E-Abstract 5055.
95. Palanker DV, Vankov A, Huie P, Fishman HA, Marmor MF, **Blumenkranz MS**. Can a self-powered retinal prosthesis support 100,000 pixels in the macula? *Invest Ophthalmol Vis Sci* 2003; 44:ARVO E-Abstract 5067.
96. Mehenti NZ, Peterman MC, Leng T, Marmor MF, **Blumenkranz MS** et al. A retinal interface based on neurite micropatterning for single cell stimulation. *Invest Ophthalmol Vis Sci* 2003; 44:ARVO E-Abstract 5069.
97. Fishman HA, Peterman MC, Marmor MF, **Blumenkranz MS**. The artificial synapse chip: Multi-cellular neurotransmitter-based retinal stimulation. *Invest Ophthalmol Vis Sci* 2003; 44:ARVO E-Abstract 5080.
98. Yellachich D, Leng T, Huie P, Noolandi J, **Blumenkranz MS**, Marmor MF, and Fishman HA. Autologous iris pigment epithelium cultured on cellulose acetate membrane transplanted into the subretinal space of rabbits. *Invest Ophthalmol Vis Sci* 2004; 45: E-Abstract 5168.
99. Leng T, Huie P, Yellachich D, Noolandi J, **Blumenkranz MS**, Marmor MF, and Fishman HA. Cellulose acetate membranes as an artificial support in subretinal RPE and IPE transplantation. *Invest Ophthalmol Vis Sci* 2004; 45: E-Abstract 5164.
100. Palanker DV, Vankov A, Fishman HA, **Blumenkranz MS**, and Marmor MF. Physical constraints on resolution of the electronic retinal prosthesis. *Invest Ophthalmol Vis Sci* 2004; 45: E-Abstract 4209.
101. Huie P, Palanker D, Vankov A, Aramant RB, Seiler MJ, Fishman HA, Marmor MF, and **Blumenkranz MS**. Migration of neural retina through a perforated membrane implanted in the subretinal space of RCS rats: implications for prosthetics. *Invest Ophthalmol Vis Sci* 2004; 45: E-Abstract 4202.

**PUBLISHED ABSTRACTS (Continued)**

102. Mehenti N, Marmor MF, **Blumenkranz MS**, Bent SF, and Fishman HA. Development of a flexible, microfabricated retinal interface. *Invest Ophthalmol Vis Sci* 2004; 45: E-Abstract 4186.
103. Kossakiewicz MJ, Ta CN, He L, Klauss V, **Blumenkranz MS**, and Miño de Kaspar H. Antibiotic resistant pattern of conjunctival streptococci. *Invest Ophthalmol Vis Sci* 2004; 45: E-Abstract 4001.
104. Ta CN, Kossakiewicz M, He L, **Blumenkranz MS**, and Miño de Kaspar H. Impact of topical Ofloxacin on the resistance rate of coagulase–negative staphylococci to fluoroquinolones in patients undergoing intraocular surgery. *Invest Ophthalmol Vis Sci* 2004; 45: E-Abstract 4000.
105. Fishman HA, Palanker DV, Mehenti NZ, Marmor MF, Bent SF, and **Blumenkranz MS**. Design of a neurotransmitter–based retinal prosthetic chip powered by the ambient light. *Invest Ophthalmol Vis Sci* 2004; 45: E-Abstract 3402.
106. Moshfeghi DM, Kumm J, Palanker DV, and **Blumenkranz MS**. Rapid algorithm for registration of multimodal images in quantitative angiography. *Invest Ophthalmol Vis Sci* 2004; 45: E-Abstract 2404.
107. **Blumenkranz MS**, Vankov A, Huie P, and Palanker D. Electro–adhesive tissue manipulator for vitreoretinal surgery. *Invest Ophthalmol Vis Sci* 2004; 45: E-Abstract 1045.
108. He L, Ta CN, Nguyen EV, **Blumenkranz MS**, and Miño de Kaspar H. Three day application of topical Ofloxacin does not induce fluoroquinolone–resistant coagulase–negative staphylococci. *Invest Ophthalmol Vis Sci* 2004; 45: E-Abstract 523.
109. Agurto–Rivera R, Yellachich D, Quiróz–Mercado H, Alvarez–Rivera G, **Blumenkranz MS**, Molnar FE, Leng T, Dalal R, Marmor MF, and Noolandi J. Subretinal implant of polycarbonate membrane in pig model, tomographic and histological results at eleven weeks. *Invest Ophthalmol Vis Sci* 2005; 46: E-Abstract 5471.
110. Palanker DV, Vankov A, Huie P, Asher A, Baccus SA, Marmor MF, and **Blumenkranz MS**. Design of a high–resolution optoelectronic retinal prosthesis. *Invest Ophthalmol Vis Sci* 2005; 46: E-Abstract 5278.
111. Molnar FE, Lombardi L, Berker N, Yeh E, Yellachich D, Leng T, Dalal R, Marmor MF, Fishman HA, and **Blumenkranz MS**. Synthetic Bruch's membrane substitutes: comparisons after subretinal transplantation with cultured iris pigment epithelium. *Invest Ophthalmol Vis Sci* 2005; 46: E-Abstract 4154.

**PUBLISHED ABSTRACTS (Continued)**

112. Lombardi L, Leng T, Yeh E, Molnar F, Noolandi J, Marmor MF, Fishman HA, and **Blumenkranz MS**. Full thickness retinal pigment epithelium explants proliferate into epithelial monolayers on synthetic Bruch's membrane substitutes. *Invest Ophthalmol Vis Sci* 2005; 46: E-Abstract 4152.
113. Moshfeghi DM and **Blumenkranz MS**. Posterior retinal break as a cause of vitreous hemorrhage in diabetes. *Invest Ophthalmol Vis Sci* 2005; 46: E-Abstract 1471.
114. Huie P, Chan I, Vankov A, Butterwick A, Marmor M, **Blumenkranz MS** et al. Retinal migration into 3-dimensional subretinal prosthetic implants. *Invest Ophthalmol Vis Sci* 2006 47: E-Abstract 3215.
115. Wu KH, Wang G, Berker N, **Blumenkranz MS**, Sanislo S. Comparison of intravitreal Triamcinolone with photodynamic therapy and photodynamic therapy alone for choroidal neovascularization secondary to age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2006 47:E-Abstract 359.
116. Kuppermann BD, Williams GA, **Blumenkranz MS**, Dugel P, Haller JA et al. Efficacy and safety of a novel intravitreal dexamethasone drug-delivery system after applicator or incisional placement in patients with macular edema. *Invest Ophthalmol Vis Sci* 2006 47: E-Abstract 5913.
117. Stanzel BV, Binder S, **Blumenkranz MS**, Marmor MF. Culture of human RPE from aged donors on a potential Bruch's membrane prosthesis. *Invest Ophthalmol Vis Sci* 2006 47: E-Abstract 1407.
118. Yellachich D, Palanker D, Andersen DE, Wiltberger MW, Mordaunt D, Marcellino GR, Morales-Canton V, Quiroz-Mercado H, **Blumenkranz MS**. Semi-automated pan-retinal photocoagulation in patients with diabetic retinopathy. *Invest Ophthalmol Vis Sci* 2006 47: E-Abstract 994.
119. Palanker DV, Yellachich D, Andersen DE, Wiltberger MW, Mordaunt D, Marcellino GR, **Blumenkranz MS**. Semi-automated patterned retinal photocoagulation. *Invest Ophthalmol Vis Sci* 2006 47: E-Abstract 968.
120. Palanker DV, Jain A, Paulus Y, Andersen, DE, **Blumenkranz MS**. Rapid and confined retinal photocoagulation using millisecond pulses. *Invest Ophthalmol Vis Sci* 2007 48: E-Abstract 4168.
121. Stanzel BV, Huie P, **Blumenkranz MS**, Binder S, Marmor MF. Towards prosthetic replacement of Bruch's membrane: Comparison of polyester and electrospun nanofiber membranes. *Invest Ophthalmol Vis Sci* 2007 48: E-Abstract 5085.

122. Pilyugina SA, Huie P, **Blumenkranz MS**. Modified Scleral Buckle: Extraconjunctival Approach. *Invest Ophthalmol Vis Sci* 2007; 48: E-Abstract 2237.
123. **Blumenkranz MS**, Dugel PU, Solley WA, Kleinman DM, Weber DA, Williams GA, Haller JA. A Randomized Dose-Escalation Trial of Locally-Administered Sirolimus to Treat Diabetic Macular Edema. *Invest Ophthalmol Vis Sci* 2008; 49: E-Abstract 1567.
124. Wong LJ, Desai RU, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, **Blumenkranz MS**. Potential Adverse Events Associated With Intravitreal Bevacizumab for Retinal and Choroidal Vascular Disease. *Invest Ophthalmol Vis Sci* 2008; 49: E-Abstract 254.
125. Dugel PU, Quiroz-Mercado H, Kleinman DM, Weber DA, Williams GA, Haller JA, **Blumenkranz MS**. Interim Analysis of a Randomized Dose-Escalation Trial of Locally-Administered Sirolimus to Treat Choroidal Neovascularization Secondary to Age-Related Macular Degeneration . *Invest Ophthalmol Vis Sci* 2008; 49: E-Abstract 582.
126. **Blumenkranz MS**, Dugel PU, Solley Wa, Kleinman DM et al. A Randomized Dose-Escalation Trial of Locally-Administered Sirolimus to Treat Diabetic Macular Edema. *Invest Ophthalmol Vis Sci* 2008; 49: E-Abstract 1567.
127. Nomoto H, Paulus YM, Dalal R, Gariano RF, Palanker D, **Blumenkranz MS**. The effect of triamcinolone acetonide on the healing of retinal photocoagulation lesions. *Invest Ophthalmol Vis Sci* 2009; 50: E-Abstract 215.
128. Desai RU, Charalel R, Jain A, Feliciano D, Sanislo SR, Moshfeghi DM, **Blumenkranz MS**, Vollrath D. An analysis of CFH and LOC387715 genotypes in age-related macular degeneration patients: Response to photodynamic therapy vs. anti-VEGF therapy. *Invest Ophthalmol Vis Sci* 2009; 50: E-Abstract 230.
129. Vanchinathan V, Huie P, Noolandi J, Waters DJ, Hartmann L, Frank CW, Cochran JR, **Blumenkranz MS**, Ta CN, and Stanford-SERI Study Group Program. Corneal inlay of biomimetic interpenetrating network hydrogel in rabbit. *Invest Ophthalmol Vis Sci* 2009; 50: E-Abstract 2194.
130. Culbertson WW, Schuele G, Wiltberger MW, Gooding P, Angeley D, Friedman NJ, Seibel B, Talamo JH, Palanker D, **Blumenkranz MS**. Oct-Guided Femtosecond Laser System for Cataract Surgery. *Invest Ophthalmol Vis Sci* 2010 51: E-Abstract 5445.
131. Rentz AM, Kowalski J, Revicki D, Loewenstein A, **Blumenkranz MS** et al. Normative comparison of generic- and vision-targeted health-related quality of life (HRQL) outcomes in patients with vision loss due to macular edema following retinal vein occlusion. *Invest Ophthalmol Vis Sci* 2010 51: E-Abstract 4728.
132. He L, Chan A, Leung L-S, **Blumenkranz M**. Acute changes in central macular thickness and volume after intravitreal Triamcinolone and Bevacizumab for macular edema associated with diabetic retinopathy and retinal vein occlusion. *Invest Ophthalmol Vis Sci* 2010 51: E-Abstract 4243.

**PUBLISHED ABSTRACTS (Continued)**

133. Bandello F, **Blumenkranz MS**, Jiao J, Li X-Y, Whitcup S. 12-month evaluation of Dexamethasone intravitreal implant in patients with macular edema due to central retinal vein occlusion. *Invest Ophthalmol Vis Sci* 2010 51: E-Abstract 6397.
134. Belfort R, Jr., Heier JS, Haller JA, Blumenkranz MS, et al. Benefits of early treatment with Dexamethasone intravitreal implant in patients with macular edema due to BRVO or CRVO over 12 months. *Invest Ophthalmol Vis Sci* 2010 51: E-Abstract 6398.
135. Paulus Y, de la Zerda A, Teed R, Bodapati S, Dollberg Y, Khuri-Yakub B, **Blumenkranz MS** et al. Ophthalmic Photoacoustic Imaging for Blood Distribution Evaluation. *Invest Ophthalmol Vis Sci* 2011; 51:6573.